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A Potential Role For Sap97 In Psychiatric Disorders
Abstract
The goal of this dissertation is to further understand the genetic architecture of neuropsychiatric disorders,
such as autism spectrum disorder (ASD) and schizophrenia (SCZ). We attempt to understand the functional
significance of the gene synapse associated protein of 97KDa (SAP97) and identify a novel role for SAP97 in
the etiology of neuropsychiatric disorders.
SAP97 belongs to a family of scaffolding proteins, the membrane-associated guanylate kinases (MAGUKs),
that are highly enriched in the postsynaptic density of synapses and play an important role in organizing
protein complexes necessary for synaptic development and plasticity. Large-scale genetic studies have
implicated MAGUKs in neuropsychiatric disorders such as intellectual disability, ASD, and SCZ, but knock-
out mice have been impossible to study because the Sap97 null mice die soon after birth due to a craniofacial
defect. In Chapter 2, we studied the transcriptomic and behavioral consequences of a viable, brain-specific
conditional knockout of Sap97 (SAP97-cKO). RNA sequencing (RNAseq) from hippocampi from control
and SAP97-cKO male animals identified 67 differentially expressed transcripts, which were specifically
enriched for SCZ-related genes. Subjecting SAP97-cKO mice to a battery of behavioral tests revealed a subtle
anxiety-like phenotype present in both male and female SAP97-cKO animals, as well as a mild male-specific
cognitive deficit and female-specific motor learning deficit. Collectively, this work suggests that loss of Sap97
alters behavior, and may contribute to some of the endophenotypes present in SCZ. In Chapter 3, we discuss
how the SAP97-cKO mouse may serve as a novel model system for interrogating aspects of the cellular and
molecular defects underlying SCZ and other related neuropsychiatric disorders.
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ABSTRACT 
 
A POTENTIAL ROLE FOR SAP97 IN PSYCHIATRIC DISORDERS 
Preetika Gupta 
Robert G. Kalb 
 
The goal of this dissertation is to further understand the genetic architecture of 
neuropsychiatric disorders, such as autism spectrum disorder (ASD) and schizophrenia 
(SCZ).  We attempt to understand the functional significance of the gene synapse 
associated protein of 97KDa (SAP97) and identify a novel role for SAP97 in the etiology 
of neuropsychiatric disorders. 
 
SAP97 belongs to a family of scaffolding proteins, the membrane-associated guanylate 
kinases (MAGUKs), that are highly enriched in the postsynaptic density of synapses and 
play an important role in organizing protein complexes necessary for synaptic 
development and plasticity.  Large-scale genetic studies have implicated MAGUKs in 
neuropsychiatric disorders such as intellectual disability, ASD, and SCZ, but knock-out 
mice have been impossible to study because the Sap97 null mice die soon after birth 
due to a craniofacial defect.  In Chapter 2, we studied the transcriptomic and behavioral 
consequences of a viable, brain-specific conditional knockout of Sap97 (SAP97-cKO).  
RNA sequencing (RNAseq) from hippocampi from control and SAP97-cKO male animals 
identified 67 differentially expressed transcripts, which were specifically enriched for 
SCZ-related genes.  Subjecting SAP97-cKO mice to a battery of behavioral tests 
revealed a subtle anxiety-like phenotype present in both male and female SAP97-cKO 
animals, as well as a mild male-specific cognitive deficit and female-specific motor 
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learning deficit.  Collectively, this work suggests that loss of Sap97 alters behavior, and 
may contribute to some of the endophenotypes present in SCZ.  In Chapter 3, we 
discuss how the SAP97-cKO mouse may serve as a novel model system for 
interrogating aspects of the cellular and molecular defects underlying SCZ and other 
related neuropsychiatric disorders.  
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CHAPTER 1: INTRODUCTION 
 
This thesis attempts to elucidate the potential contribution of SAP97 to 
neuropsychiatric disorders, such as autism spectrum disorder and schizophrenia.  In 
particular, we examine the effects of loss of Sap97 to mouse behavior and alterations in 
the transcriptome.  Here, I will outline the critical information needed to understand the 
progress made in this subject.     
 
SYNAPTOPATHIES: DISORDERS OF THE SYNAPSE 
  
 The genomic revolution has transformed the field of neuroscience by providing a 
platform to decipher the brain and its disorders.  Advancements in whole exome and 
deep sequencing technologies allow for examination of the genetic architecture of 
psychiatric disorders using large patient cohorts.  These large-scale genetic studies 
have implicated key overlapping molecular and cellular pathways that are impacted 
across mental disorders, such as chromatin regulation and the post-synaptic density, 
with dysfunction of the synapse being a convergence point (Grant, 2012; De Rubeis et 
al., 2014; McCarthy et al., 2014; Ardiles et al., 2017; Luo et al., 2017).  This observation 
coined the term “synaptopathies,” or diseases of the synapse, to collectively classify 
these disorders.   
 Human mutations in genes encoding synaptic proteins are increasingly identified 
in neurodevelopmental disorders such as epilepsy, intellectual disability, autism 
spectrum disorder, and schizophrenia.  While these disorders each present with unique 
symptoms, there is increasing recognition of the overlapping comorbidities between 
these disorders, in addition to the large genetic heterogeneity within these disorders 
2 
 
(Luo et al., 2017).  As a result, addressing the common underlying genetic mechanisms 
may be key for developing therapies across a broad range of behavioral symptoms.   
In this thesis, we choose to focus on the potential contribution of SAP97 to 
autism spectrum disorder and schizophrenia, two neuropsychiatric conditions that are 
prevalent in today’s society and share a subset of risk-associated genes.  Below, we 
provide a background for each disorder, and discuss both the importance and 
complications associated with each current genetic model.  
 
AUTISM SPECTRUM DISORDERS 
 Epidemiology and clinical presentation 
 
 Autism spectrum disorder (ASD) is diagnosed in approximately 1 out of 110 
children in the United States and is 4-5 times more common in male children than in 
females (The Autism Genome Project Consortium, 2007; Sungur et al., 2017).  Newer 
prospective studies of younger siblings of children with ASD who are at elevated risk 
provide evidence that the age of onset for the majority of cases of ASD is the second 
year of life (Zwaigenbaum et al., 2006; Martínez-Pedraza and Carter, 2009).  Several 
studies document that the mean age at which parents first report concerns to a medical 
professional is between 18 and 24 months of age (Sullivan et al., 2007; Martínez-
Pedraza and Carter, 2009).  Although ASD behaviors lie on a continuum in the general 
population, individuals with ASD are characterized by severe and pervasive impairments 
in reciprocal social interaction and communication and exhibit stereotyped behaviors, as 
well as restricted interests and activities (Martínez-Pedraza and Carter, 2009).  Most 
parents first report concerns in the area of speech and language in addition to extreme 
sensory over-or underreactivity and disturbances in the acquisition of social 
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communication, play, and motor development (Young et al., 2003).  Parents also report 
concerns regarding sleep and eating, which may be associated with sensory sensitivities 
or with the insistence on sameness (Goodlin-Jones et al., 2008; Sharp et al., 2013). 
 
Neuropathologic profile of ASD 
Neuropathologic explorations in human postmortem tissue allow for investigation 
at the cellular and cytoarchitectural levels from individuals with ASD.  Global brain 
development abnormalities are seen in the archicortex, cerebellum, brainstem, and other 
subcortical structures, with region-specific severity of neuropathology in young children 
with ASD (Wegiel et al., 2014; 2015).  Brain size as well as head circumference of a 
subset of subjects with ASD is increased compared to normal age-based values (Sacco 
et al., 2015).  An assessment of the microarchitecture of cortical areas commonly 
implicated in ASD between subjects with ASD and controls reveals disorganization of 
gray and white matter, and disorganized cortical structure and nodules of misplaced 
neurons (Casanova et al., 2013; Stoner et al., 2014; Wegiel et al., 2015).  These defects 
reflect alterations in neuronal maturation and migration processes in subjects with ASD.  
A study from one subject with ASD described finding pencil fibers consisting of 
oligodendrocytes, astrocytes, and glia that disrupted cortical lamination in the prefrontal 
cortex (Hashemi et al., 2016).   
 Young children with ASD also have significantly reduced neuronal and 
cytoplasmic volumes in the majority of examined areas compared to age-matched 
controls (Wegiel et al., 2014; 2015).  The distribution of neuronal sizes becomes more 
comparable between control and ASD individuals in adulthood, which is likely a result of 
opposing developmental trajectories (Wegiel et al., 2014; 2015).  Subjects with ASD also 
have a significant increase in neuropil, comprising the dendrites, non-myelinated axons, 
4 
 
synapses, vasculature, and glial cell processes present in between cell bodies 
(Varghese et al., 2017).  Neurons show reduced dendritic branching in the hippocampus 
of ASD subjects as compared to controls (Raymond et al., 1996).  Studies measuring 
spine density on apical dendrites in the cortex of ASD subjects report slower pruning of 
spines in the temporal lobe (Hutsler and Zhang, 2010; Tang et al., 2014).  This results in 
the difference in spine densities between ASD and controls being greater in adolescence 
than in early childhood (Tang et al., 2014).  These changes appear to be related to 
alterations that occur during early pregnancy, such as reduced programmed cell death 
and/or increased cell proliferation, altered cell migration, abnormal cell differentiation, 
abnormal neurite sprouting, and pruning that cause atypical wiring of the brain (Lacivita 
et al., 2017).  
 The biggest motivation for studying ASD is that the disorder has no known cure.  
Psychotropic medications currently available alleviate psychiatric and behavior 
problems, such as aggression, self-injury, hyperactivity, anxiety, and mood symptoms, 
but they do not have an effect on the core symptoms of ASD (Young and Findling, 
2015).  To date, the only approved drugs to treat symptoms of ASD are risperidone and 
aripiprazole, both used to treat aggression, self-injury, and severe tantrums (Lacivita et 
al., 2017).  The lack of treatment is due in part to the multifactorial nature of the disorder.   
Another motivation for studying ASD is that prevalence rates have dramatically 
increased in the past decade (Christensen et al., 2016).  There are various reasons for 
this increase, including broadening of the spectrum to include milder forms of the 
disorder, improved clinical detection, and higher public awareness (Levy et al., 2009).  
As a result, ASD has recently emerged as a major public health issue worldwide.  Due to 
the lack of promising treatment, there is an urgent need for ASD research.  One of the 
obstacles in studying the disorder is that hundreds of risk genes have been identified, 
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with not one major causative gene.  Rare variants have been identified that are highly 
penetrant, and common variants can contribute to small effect sizes (Lacivita et al., 
2017).  Below, we discuss what is currently known regarding the genetic underpinnings 
of ASD.     
 
Genetic susceptibility to ASD 
Interestingly, family genetic data supports a first-degree relative recurrence risk 
of approximately 5-10%, which points to disruption of genetic architecture as being a 
leading cause of the disease (Ritvo et al., 1989; Sumi et al., 2006).  It is believed that the 
neurocognitive phenotype of ASD is the result of a complex and highly heterogeneous 
set of genetic and environmental causes (Lacivita et al., 2017).  In some patients, the 
cause of the disorder is purely genetic (due to known chromosomal mutations), while in 
other patients, the disorder is more likely related to environmental causes such as 
prenatal exposure to chemical pollutants, toxins, viruses, or drugs (Persico and Merelli, 
2014; Lacivita et al., 2017).  For this thesis work, we have chosen to focus primarily on 
the genetic contribution to ASD and other related psychiatric disorders.  The genetic 
abnormalities associated with ASD and other related psychiatric disorders may be 
grouped into three classes: 1) at least 5% are caused by single gene mutations, 2) 
approximately 10% are copy number variations including duplications, large deletions, 
inversions, and translocations of chromosomes, and 3) many are polygenic risk factors 
due to accumulation of common variants, each contributing to a portion of the risk 
(Varghese et al., 2017).  Most research done in the laboratory to model and study the 
unique contribution of each risk-associated gene utilizes rodent models.   
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GENETIC MOUSE MODELS OF ASD 
 There are two types of animal models for ASD: environmentally induced (by 
exposure of the pregnant animals to certain toxins or infection/inflammation) and those 
that are induced by genetic manipulations.  In this introduction, we have chosen to focus 
on genetic mouse models of ASD.  More than a hundred de novo single gene mutations 
and copy-number variants have been implicated in ASD, each occurring in a small 
subset of cases (Kazdoba et al., 2015).  Mutant mouse models with syntenic mutations 
offer investigators a tool for understanding the role of each gene in modulating biological 
and behavioral phenotypes relevant to ASD (Kazdoba et al., 2015).  Investigations of 
ASD, schizophrenia, and other related psychiatric disorders indicate a highly polygenic 
architecture with small effect sizes of each implicated risk variant (Ebert and Greenberg, 
2013; Fromer et al., 2014; Kato, 2014; Smoller et al., 2018).  As a result, mouse 
modeling of these disorders by targeting one such risk variant typically demonstrates a 
moderate, or incomplete manifestation of the human disorder.  Below, we have 
highlighted the most prominent genetic mouse models of ASD.  Extensive 
characterization of these models demonstrates that while ASD is genetically complex, 
these studies are useful in describing the direct contribution of each gene.   
As mentioned previously, a remarkable number of risk genes for ASD code for 
synaptic proteins, including cell adhesion proteins, neuroligins and neurexins, and 
postsynaptic scaffolding proteins such as the PROSAP/SHANK family.  Mice with 
targeted mutations in many of these genes have been generated and characterized, as 
described below. 
 
CNTNAP2 
The contactin associated protein-like 2 (CNTNAP2) gene, a cell adhesion 
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molecule located on chromosome 7, encodes contactin-associated protein-like 2 
(CASPR2), a member of the neurexin superfamily (Rodenas-Cuadrado et al., 2013).  
Several mutations in the CNTNAP2 locus, including rare, common and deletion variants, 
have been associated with ASD (Alarcón et al., 2008; Arking et al., 2008; Rossi et al., 
2008; Poot et al., 2009).  A recessive nonsense mutation in CNTNAP2 was shown to 
cause a syndromic form of ASD, cortical dysplasia, and focal epilepsy syndrome 
(Alarcón et al., 2008; Arking et al., 2008).  The CNTNAP2 variant that increases risk for 
the language endophenotype in ASD was shown to lead to abnormal functional brain 
connectivity in human subjects (Weinstein-Fudim and Ornoy, 2016).  Knockout mice for 
the mutation show migration abnormalities, reduced number of interneurons, and 
abnormal neuronal network activity (Scott-Van Zeeland et al., 2010).  Mice lacking 
Cntnap2 also exhibit behavioral abnormalities such as reduced juvenile ultrasonic 
vocalizations, reduced social interaction time, and increased repetitive behaviors 
(Peñagarikano et al., 2011).  
 
Neuroligins and Neurexins 
Neuroligins are cell adhesion molecules located at the postsynaptic side of the 
synapse and interact with neurexins, their presynaptic partner protein (Bang and 
Owczarek, 2013).  Neuroligins contribute to synaptic neurotransmission through their 
influence on synaptic formation (Hu et al., 2015).  Neuroligin (NLGN) proteins encoded 
by X-linked genes, such as NLGN3 and NLGN4, have been associated with ASD in 
large genome-wide studies (Auranen et al., 2002; Glessner et al., 2009).  Using amino 
acid sequencing in linkage and proband case studies, deletions and frameshifts in 
NLGN3 and NLGN4 sequences have been identified in individuals with ASD (Laumonier 
et al., 2004; Lawson-Yuen et al., 2008).  Knockout mouse models have been created for 
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four neuroligin isoforms—Nlgn1, Nlgn2, Nlgn3, and Nlgn4.  Nlgn1 KO mice show 
minimal social deficits, but have increased grooming and spatial learning impairments 
along with impaired hippocampal long-term potentiation (Blundell et al., 2010).  Nlgn2 
KO mice show no social deficits, but display increased anxiety-like behavior, decreased 
pain sensitivity, and poor motor coordination (Blundell et al., 2010; Wöhr et al., 2013). In 
addition, Nlgn2 KO mice had decreased inhibitory neurotransmission, as well as 
decreased immunostaining of inhibitory synapse markers (Blundell et al., 2010).  Nlgn3 
knock-in (R451C) mice, with a ASD-related point mutation, did not display robust ASD-
like behaviors, but rather had mild developmental differences, enhanced spatial learning, 
and reduced acoustic startle (Tabuchi et al., 2007; Chadman et al., 2008; Etherton et al., 
2011).  These results would suggest that this ASD-related point mutation delayed 
development, altered learning, and reduced sensitivity to stimuli.  Nlgn knock-in mice 
also exhibited increased inhibitory neurotransmission in the barrel cortex, increased 
excitatory neurotransmission and enhanced long-term potentiation in the hippocampus, 
and increased dendritic branching in the hippocampus (Tabuchi et al., 2007; Etherton et 
al., 2011).  Nlgn3 KO mice show no social deficits, but are impaired in fear conditioning 
and olfaction, and are hyperactive.  Nlgn3 KO mice also show decreased total brain 
volume (Radyushkin et al., 2009).  And lastly, Nlgn4 KO mice show reduced sociability 
and ultrasonic vocalizations, as well as a reduction in total brain volume (Jamain et al., 
2008; El-Kordi et al., 2013).  Genetically modified mice have also been made for 
neurexins (NRXN), the neuroligin partner protein.  Numerous association studies have 
identified mutations in the NRXN1 gene, located on chromosome 2, in intellectual 
disabilities and ASD (Feng et al., 2006; Szatmari et al., 2007; Zahir et al., 2007; 
Glessner et al., 2009).  Nrxn1 KO mice display increased grooming, reduced locomotor 
activity, reduced sensorimotor gating, and increased aggression (Etherton et al., 2009; 
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Grayton et al., 2013).  Together, these studies demonstrate that the Nlgn and Nrxn 
genes may not play a prominent role in social behavior, but may instead regulate anxiety 
and cognition.   
 
SHANK/ProSAP2 Family 
The SHANK family of genes, located on chromosome 22q, encodes scaffolding 
proteins that assist in the synaptic organization of excitatory glutamatergic neurons by 
binding to postsynaptic density proteins, signaling molecules, postsynaptic receptors, 
and cytoskeletal proteins (Grabrucker et al., 2014).  Genetic studies have identified de 
novo and inherited mutations in SHANK1, SHANK2, and SHANK3 (Berkel et al., 2010; 
Boccuto et al., 2012; Sato et al., 2012).  22q13 deletion syndrome, also known as 
Phelan-McDermid syndrome, is caused by a deletion on the distal part of the long arm of 
chromosome 22 and is associated with ASD-like behaviors (Phelan and McDermid, 
2011; Kolevzon et al., 2015).  SHANK3 is one of the most commonly mutated genes 
within the Phelan-McDermid critical region (Phelan and McDermid, 2011).  Genetically-
modified mouse models have been generated and characterized for the three Shank 
isoforms.  Shank1 KO mice do not display robust social deficits, but emit fewer ultrasonic 
vocalizations and have motor impairments (Silverman et al., 2011; Wöhr et al., 2011).  
Shank1 KO mice also display dendritic spine abnormalities, including weaker basal 
synaptic neurotransmission (Hung et al., 2008). Shank2 KO mice, however, show 
reduced sociability in addition to abnormal ultrasonic vocalizations (Schmeisser et al., 
2012).  Shank2 KO mice also had reduced number of hippocampal dendritic spines and 
reduced glutamatergic neurotransmission in the hippocampus (Schmeisser et al., 2012).  
Multiple transgenic mouse models of Shank3, with deletions in various domains of the 
gene, have also been generated and characterized.  Reduced sociability, reduced 
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ultrasonic vocalizations, and high levels of repetitive self-grooming were dependent upon 
which isoform of Shank3 was deleted (Peça et al., 2011; Wang et al., 2011b; Kouser et 
al., 2013).  Reduced basal neurotransmission, as well as abnormalities in neuronal 
morphology (neuronal hypertrophy, dendritic spine deficits) have been identified in most 
of these models (Peça et al., 2011; Wang et al., 2011b; Kouser et al., 2013).  Overall, 
these studies highlight that the Shank gene family may be responsible for normal social 
behavior, maintaining normal synaptic function and neuronal structure, and that 
complete or partial loss of Shank may also induce repetitive behaviors.     
 
SCHIZOPHRENIA 
Epidemiology and clinical presentation 
 In addition to ASD, we also chose to examine the potential contribution of SAP97 
to schizophrenia (SCZ).  SCZ affects approximately 5 out of every 1000 individuals (Wu 
et al., 2006).  The age of onset varies between men and women, where men tend to 
have a younger onset, with the peak incidence for men and women lies between 15-24 
years of age (Wu et al., 2006).  Men have about a 30-40% higher lifetime risk of 
developing SCZ.  Like many other psychiatric disorders, SCZ is diagnosed by its 
symptoms, which fall into three main categories: positive, negative, and cognitive.  
Positive symptoms include hallucinations, delusions, and disorganized thinking (Lehman 
et al., 2006; Tandon et al., 2009).  Negative symptoms include social withdrawal, blunted 
affect, and a decreased in incentive motivation (Lehman et al., 2006; Tandon et al., 
2009).  Cognitive symptoms encompass deficits in processing speed, working memory, 
attentional set-shifting, and verbal memory (Lehman et al., 2006; Tandon et al., 2009).  
Typically, the negative and cognitive symptoms are more predictive for the long-term 
prognosis of the disorder (Green et al., 2000).  Similar to ASD, there is evidence 
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suggesting a strong genetic component of SCZ.  Classical twin studies demonstrated a 
50% concordance rate for SCZ among monozygotic twins and a reduced rate of 15% if 
the twins are dizygotic (Canetta and Kellendonk, 2018).  
 
Neuropathologic profile of SCZ  
Abnormalities in neurodevelopment might be responsible for the cognitive deficits 
in SCZ (Tripathi et al., 2018).  In SCZ, abnormal brain development begins as early as 
prenatal life, which intensifies during childhood and continues until adulthood (Tripathi et 
al., 2018).  Many brain areas are altered in SCZ, such as the third and lateral ventricles, 
prefrontal cortex, amygdala, medial temporal lobe, basal ganglia, thalamus, corpus 
collosum, and cerebellum (Tripathi et al., 2018).  Abnormalities in neurotransmission, 
including the neurotransmitters dopamine, serotonin, and glutamate, have also provided 
the basis for theories on the pathophysiology of SCZ (Lavretsky et al., 2008).  Other 
theories implicate aspartate, glycine, and GABA as part of the neurochemical imbalance 
of SCZ (Lavretsky et al., 2008).  The core symptoms of SCZ, such as negative 
symptoms and executive dysfunction, are thought to result directly from altered 
neuroplasticity (Voineskos et al., 2013).  SCZ alters brain derived neurotrophic factor 
(BDNF), which is associated with hippocampal neuroplasticity, attributing to the cognitive 
deficits present in the disorder (Nieto, 2013).  Abnormal activity at dopamine receptor 
sites is also thought to be associated with many symptoms of SCZ.  Low dopamine 
levels within the nigrostriatal pathway are thought to affect the extrapyramidal system, 
leading to motor symptoms (Lavretsky et al., 2008; Patel et al., 2014).  The mesolimbic 
pathway may play a role in the positive symptoms of SCZ in the presence of excess 
dopamine (Lavretsky et al., 2008; Patel et al., 2014).  Negative symptoms and cognitive 
deficits may also be due to low mesocortical dopamine levels (Lavretsky et al., 2008). 
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One of the leading motivations for studying SCZ is that is has no known cure.  
Current pharmacological agents, such as second-generation antipsychotics, are used to 
treat the symptoms of the disorder rather than the underlying cause (Lewis and 
Lieberman, 2018).  However, similar to ASD and many other neuropsychiatric disorders, 
one obstacle in studying the genetic cause of SCZ is that whole genome studies have 
identified over 100 gene variants that are associated with the disorder (Schizophrenia 
Working Group of the Psychiatric Genomics Consortium, 2014).  While few studies of 
common variants have produced important insight into possible biological mechanisms 
of SCZ, most common variants only minimally increase the risk for the disorder.  In order 
to elucidate the contributions of each genetic variant to the etiology of SCZ, various 
genetic mouse models have been generated and characterized.   
 
GENETIC MOUSE MODELS OF SCHIZOPHRENIA 
 SCZ has both genetic and environmental components, and an attempt has been 
made to model both aspects of the disorder.  In this thesis introduction, we focus on 
describing genetic models of SCZ.  Several mouse models have been useful for 
studying the behavioral consequences of specific synaptic gene alterations and the 
mechanisms potentially underlying the pathogenesis of SCZ.   
 
Neuregulin  
Neuregulin 1 (NRG1) is part of a family of growth and differentiation factors, and 
was first suggested as a potential candidate gene for SCZ in a study of the Icelandic 
population (Stefansson et al., 2002).  This association between NRG1 and SCZ was 
later confirmed in Scottish and Irish populations (Stefansson et al., 2002; Corvin et al., 
2004).  NRG1 is essential for neurodevelopment, with key roles in synapse formation, 
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neuronal migration, synaptic plasticity, and regulation of neurotransmitter systems (Falls, 
2003).  While homozygous null mice for Nrg1 die midgestation, heterozygous mutant 
mice are viable (Gerlai et al., 2000).  Nrg1 hypomorph epidermal growth factor-like 
domain models result in hyperactivity with impaired PPI (Gerlai et al., 2000; Duffy et al., 
2008).  Additionally, most NRG1 proteins are synthesized with a transmembrane (TM) 
domain, and Nrg1 hypomorph TM models also result in hyperactivity and exhibit 
impaired PPI, altered habituation, increased aggression, and decreased functional 
NMDA receptors (Stefansson et al., 2002; Karl et al., 2007; O'Tuathaigh et al., 2008).  
Nrg1 immunoglobulin-like domain mutant mice, while not hyperactive, are impaired in 
the latent inhibition task (Rimer et al., 2005).  A more recent model focusing on the 
deletion of a specific Nrg1 isoform (Type III) produces mice with a more pronounced PPI 
deficit, impaired performance on delayed alteration memory tasks, enlarged lateral 
ventricles, and decreased spine density (Chen et al., 2008).  Collectively, these studies 
indicate that Nrg1 may play a more prominent role in the sensorimotor gating phenotype 
of SCZ, while its effects on activity and memory remain unclear.   
 
DISC1  
Disrupted-in-schizophrenia-1 (DISC1) was identified as a candidate gene when it 
was found to be disrupted by a balanced translocation that cosegregates with SCZ and 
related psychopathologies (Millar et al., 2000; 2001).  DISC1 plays an important role in 
neurite outgrowth, cell migration, and cell signaling (Mackie et al., 2007).  A mutant 
mouse model of Disc1 carrying a deletion variant displayed impairments in working 
memory, deceased mPFC volume, altered synaptic transmission in the hippocampus, 
and reduced dendritic growth in the dentate gyrus (Koike et al., 2006; Kvajo et al., 2008).  
An inducible Disc1 C-terminal fragment transgenic model exhibited abnormal spatial 
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working memory, deficits in social interaction, and decreased hippocampal dendritic 
complexity (Li et al., 2007).  A model expressing the dominant negative C-terminal 
truncated Disc1 exhibited hyperactivity, disrupted PPI, depressive-like symptoms, and 
enlarged lateral ventricles (Hikida et al., 2007).  Inducible expression of mutant human 
DISC1 also produced mice with enlarged lateral ventricles, deficits in spatial working 
memory, impaired social interaction, and hyperactivity (Pletnikov et al., 2007).  And 
lastly, truncated Disc1 transgenic mice exhibit enlarged lateral ventricles, decreased 
cortical neurogenesis, increased immobility and reduced vocalization in depression-
related tests, as well as impairment in latent inhibition (Shen et al., 2008).  These studies 
demonstrate that while Disc1 clearly contributes to the pathophysiology of SCZ, the 
nature of the mutation has profound effects on the range of observed behavioral 
phenotypes.    
 
Dysbindin 
Several studies have implicated dysbindin (DTNBP1) as a SCZ candidate gene 
(Straub et al., 2002; Tang et al., 2003; Kirov et al., 2004).  DTNBP1 binds to 
dystrobrevins, components of the dystrophin-associated glycol-protein complex (DGC), 
and is thought to play a fundamental role in regulating synaptic structure and signaling 
(Benson et al., 2001).  Dtnbp1 deletion mice on a DBA/2J background strain were found 
to have increased anxiety and impaired social interaction, as well as deficits in working 
and recognition memory (Hattori et al., 2008; Takao et al., 2008).  These mice also 
displayed increased freezing response to a conditioned stimulus, suggesting deficits in 
emotional and motivated learning and memory (Bhardwaj et al., 2009).  These mice also 
had decreased dopamine levels, reduced steady state levels of snapin (synaptic priming 
regulator), and deficiencies in neurosecretion (Murotani et al., 2007; Feng et al., 2008; 
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Chen et al., 2008a).  However, a study of Dtnb1 KO mice on a C57Bl/6 strain showed no 
evidence of increased anxiety, although replicated the spatial learning and memory 
deficit (Cox et al., 2009).  While Dtnb1 partially contributes to a SCZ phenotype, the 
extent remains unclear due to complications with the background strain.   
 
22q11.2 deletion 
 The 22q11.2 deletion is a rare chromosomal mutation spanning ~3 Mb that has 
also been associated with SCZ (Drew et al., 2011).  22q11.2 deletion syndrome 
(22q11DS) is characterized by a 25-fold increased risk for developing SCZ as well as 
cardiac and facial anomalies (Karayiorgou et al., 2010).  This deletion syndrome also 
increases the risk of other psychiatric disorders, such as attention-deficit hyperactivity 
disorder, bipolar disorder, anxiety, and affective disorders (Murphy et al., 1999; 
Niklasson et al., 2001).  22q11.2 microdeletion carriers also show language delay, 
decreased full scale IQ, learning disabilities and mental retardation, and deficits in 
attention and working memory (Niklasson, 2001; Karayiorgou et al., 2010).  Although this 
rare microdeletion is present in only 1-2% of patients with SCZ, its high penetrance for 
the disease makes 22q11DS genetic models an excellent opportunity to investigate the 
pathogenesis underlying certain behavioral abnormalities present in SCZ and other 
related disorders (Karayiorgou et al., 2010).   
 A region of mouse chromosome 16 is homologous to the 22q11.2 region in 
humans, containing murine versions to all genes except CLTCL1, with minimal 
reorganization of gene order (Paylor and Lindsay, 2006).  Several mouse models have 
been generated and characterized with deletions that fall within or encompass the 
microdeletion (Drew et al., 2011).  For example, the Df(16)A+/- mice show impairments 
in the acquisition of a delayed non-match to sample T-maze task that relies on spatial 
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working memory (Stark et al., 2008).  These mice also display reduced synchronous 
activity between the dorsal hippocampus and medial prefrontal cortex during task 
acquisition, suggesting that deficits in communication between the hippocampus and 
prefrontal cortex may underlie working memory impairments (Sigurdsson et al., 2010).  
Another 22q11DS mouse model, Df(16)1+/-, showed weakened auditory thalamocortical 
connections in post-adolescent, but not pre-adolescent animals, mirroring the 
developmental timeline of behavioral impairments in PPI in these mice (Chun et al., 
2014).  This reduction in thalamocortical strength was specific to the auditory cortex, and 
was due to an unexpected increase in dopamine D2 receptors in the medial geniculate 
nucleus of the thalamus (Chun et al., 2014).  Thalamocortical strength and PPI were 
normalized following acute administration of haloperidol, suggesting that the therapeutic 
effects of antipsychotic medications in SCZ could be due to targeting thalamic D2 
receptors (Chun et al., 2014).  Overall, the 22q11DS mouse models may highlight the 
SCZ-related behaviors, along with the associated mechanisms, linked to this 
chromosomal region.   
 
SIGNIFICANCE OF CURRENT RODENT MODELS 
 The above discussion of current and popular rodent models for ASD and/or SCZ 
highlight the polygenic origin of these disorders.  The literature suggests that, at least in 
the mouse, disruption of a single gene is typically not the cause of psychiatric disorder.  
However, study of these risk variants in genetically modified mice allow us the means to 
elucidate which behavioral domains are regulated by each candidate gene.  
Furthermore, we can investigate the specific molecular and cellular pathways regulated 
by each candidate gene that underlie the behavioral domain(s) in question.  In this thesis 
work, we make the first attempt to understand the contribution of candidate gene SAP97 
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to psychiatric disorders such as ASD and SCZ.  Below, we discuss the background of 
SAP97’s gene family, the membrane associated guanylate kinases.  We discuss their 
significance in synapse biology and the current evidence suggesting their role in 
psychiatric disorders.      
 
MEMBRANE ASSOCIATED GUANYLATE KINASES 
 In this section of the introduction, we discuss the membrane associated 
guanylate kinases (MAGUKs), an integral group of synaptic genes known to play a 
prominent role in a broad range of psychiatric disorders, including ASD and SCZ.  We 
choose to focus in depth on the MAGUK family as it is extensively expressed in the brain 
and well conserved throughout evolution.  Below, we provide a general background and 
rationale for focusing on the contribution of MAGUKs to ASD, SCZ, and other related 
psychiatric disorders. 
 
MAGUK Subfamily Classification 
The MAGUK protein family is classified phylogenetically in 10 subfamilies by 
comparison of the genomic sequences of the core PDZ-SH3-GUK region and by the 
supplemental domains they possess (Oliva et al., 2011).  Of the ten MAGUK 
subfamilies, members of the subfamilies DLG, CASK, MPP, CACNB, and MAGI are 
expressed in the central nervous system (CNS) where they play various roles in the 
formation and function of synapses (Laura et al., 2002; Jing-Ping et al., 2005; Deng et 
al., 2006).  Members of the ZO family are not expressed in neurons, but are present in 
the brain where they play an import role in the formation and maintenance of the blood-
brain barrier (Wolburg and Lippoldt, 2002).  The DLG and CASK subfamilies are the 
most well-studied MAGUKs due to their clear role in synapse formation and function 
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(Oliva et al., 2011).  While both subfamilies are also expressed in epithelial tissues and 
the peripheral nervous system, previous groups have focused on their function in the 
CNS (Oliva et al., 2011).  For this body of work, we have chosen to focus on the DLG 
subfamily of MAGUKs. 
 
Expression Pattern of the DLG MAGUK Subfamily 
The DLG subfamily of MAGUKs (Dlg-MAGUK) is expressed in the CNS at all 
stages of development (Kim and Sheng, 2004; Funke et al., 2005).  All members can be 
found presynaptically and postysnaptically, however some are mainly found in the 
postsynaptic compartment of excitatory synapses and restricted to the postsynaptic 
density (Kim and Sheng, 2004; Funke et al., 2005).  The Dlg-MAGUK family also differs 
in their temporal and spatial expression.  PSD-95 is expressed at low levels during 
embryonic and early postnatal development, but is enhanced during postnatal 
development, and reaches maximum expression at adulthood (Hsueh and Sheng, 1998; 
Al-Hallaq et al., 2001).  PSD-93 shows a similar expression profile to PSD-95 in the 
hippocampus (Sans et al., 2000).  SAP102, however, is highly expressed in the 
hippocampus during the first postnatal week, remains stable by postnatal day P35, and 
decreases into adulthood (Muller et al., 1996; Sans et al., 2000).  SAP97 displays an 
expression pattern opposite to PSD-95 and PSD-93 in the hippocampus and other brain 
tissues, where expression levels decrease from embryo to adult stages (Cai et al., 
2008).  This observation suggests that SAP97 participates in developmental processes 
of the nervous system (Cai et al., 2008).   
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The role of Dlg-MAGUKs in Synapse Formation and Function 
The expression pattern of Dlg-MAGUKs during development suggests that they 
are involved in the regulation of synaptogenesis, a highly regulated process of building 
neural circuits.  Studies done in mammals as well as Drosophila neuromuscular junction 
suggest that Dlg-MAGUKs are necessary for the clustering and stabilization of glutamate 
receptors once the pre- and postsynaptic sites have been contacted and stabilized by 
adhesion proteins (Chen and Featherstone, 2005; Waites et al., 2009).  The participation 
of Dlg-MAGUKs in the maturation of mammalian synapses has been shown via 
overexpression experiments.  Overexpression of PSD-95 and SAP97 increases the size 
of spines and the formation of multi-innervated spines in hippocampal neurons 
(Nikonenko et al., 2008; Poglia et al., 2010).  Additionally, overexpression of SAP97 
promotes dendritic growth and requires the binding to the AMPA receptor subunit 
(AMPAR), GLUA1 (Zhou et al., 2008).  SAP97, PSD-95, and SAP102 overexpression 
also enhance the expression of presynaptic proteins such as synatophisin, synapsin, 
and bassoon (Regalado, 2006).  The overexpression of several PSD-95 interacting 
proteins also has an effect in spine morphogenesis (Lee et al., 2008).   
 While Dlg-MAGUK overexpression studies have been informative, loss of 
function experiments have not produced consistent results.  Knockout mice for Psd-95, 
Psd-93, or Sap102 do not have defects in synapse development (Miguad et al., 1998; 
McGee et al., 2001; Cuthbert et al., 2007).  Psd-95 mice carrying a targeted mutation 
that introduces a stop codon in the third PDZ domain show only altered dendritic spine 
density in the hippocampus (Vickers et al., 2006).  Moreover, acute knockdown of Psd-
95 using shRNA does not produce defects in dendritic spine density in primary 
hippocampal cultures (Elias et al., 2006).  Sap97 knockout animals have not been 
possibly to study, as the mutant mice display a cleft palate and die prematurely 
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(Caruana and Bernstein, 2001).  However, studies conducted on neuronal cultures from 
Sap97 knockout animals do not show any defect in glutamate receptor distribution or 
AMPAR mediated currents (Howard et al., 2010).  As it has been demonstrated that 
PSD-95, PSD-93, and SAP102 can compensate for each other, the lack of defects 
observed in the knockout mice can be explained by functional redundancy (Elias et al., 
2006; Howard et al., 2010).    
 The Dlg-MAGUK family also plays an integral role in glutamate receptor 
clustering and trafficking, both of which are essential processes for the efficiency and 
plasticity of glutamatergic synapses.  PSD-95 is the most well-studied Dlg-MAGUK for its 
role in clustering and trafficking glutamate receptors, especially NMDARs (Elias and 
Nicoll, 2007).  PSD-95 is also implicated in the trafficking of AMPARs, although indirectly 
via transmembrane AMPAR regulatory proteins (TARPs) (Chen et al., 2000).   
 SAP97 has been implicated in receptor trafficking by various studies.  Sap97 
occurs as two splice variants (α and β).  SAP97α is mostly found at the postsynaptic 
density, while SAP97β is found in the perisynaptic region (Oliva et al., 2011).  Both 
splice variants are able to bind the GLUA1 AMPAR (Oliva et al., 2011).  Current 
evidence suggests that the ratio between these two isoforms can regulate the 
distribution of GLUA1, and as a result, synaptic strength (Waites et al., 2009).  Acute 
overexpression of SAP97β promotes trafficking of AMPARs and NMDARs to the 
synapse in immature pyramidal neurons but not in mature neurons (Howard et al., 
2010).  However, chronic overexpression in vivo during development enhances synaptic 
transmission in mature neurons (Howard et al., 2010).  These findings suggest that 
SAP97β plays a role in receptor trafficking during development rather than in adult 
plasticity.   
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THE CONTRIBUTION OF MAGUKs TO PSYCHIATRIC DISORDERS  
The prominent role of Dlg-MAGUKs at glutamatergic synapses and in synaptic 
plasticity suggests that mutations in MAGUK genes would be involved in synaptic-
related disorders, notably ASD and SCZ.  Below, we outline the evidence implicating the 
Dlg-MAGUKs in ASD, SCZ, and related neuropsychiatric disorders, and discuss the 
current genetic models available.  
Sequencing techniques and analytics have been used to identify PSD-95 
mutations in ASD and SCZ patients.  Whole-exome sequencing studies of SCZ and ASD 
patients show disrupted mutations of proteins located in excitatory synapses of the PSD, 
such as NMDAR and PSD-95 (Fromer et al., 2014; Purcell et al., 2014).  Studies from 
postmortem SCZ patients reveal a significant decrease in PSD-95 mRNA and protein 
expression levels in the dorsolateral and dorsomedial prefrontal cortex, suggesting an 
association between PSD-95 dysfunction and SCZ (Ohnuma et al., 2000; Catts et al., 
2016).  PSD-95 is also involved in a network of interactions with high-risk ASD genes 
that include SHANK, HOMER, NLGN, and FMR1 (Gilman et al., 2011; Tsai et al., 2012; 
De Rubeis et al., 2014).  Furthermore, PSD-95 is a candidate gene disrupted in 
intellectual disability, a cognitive disorder characterized by a reduction of dendritic spines 
(Lelieveld et al., 2016).  PSD-95 has direct interactions with intellectual disability-related 
proteins within the excitatory PSD that include ARC and IL1RAPL1, which are 
responsible for regulating spine density and function (Pavlowsky et al., 2010; Valnegri et 
al., 2011; Fernández et al., 2017).  To model with in mice, null animals have been made 
and characterized.  Feyder et al. characterized the Psd-95 knockout mice and the mice 
exhibit increased repetitive behaviors, abnormal communication, hyper-social behavior, 
impaired motor coordination, and increased stress-reactivity and anxiety-related 
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responses (Feyder et al., 2010).  The extent to which the Psd-95 null mice faithfully 
report on the contribution of Psd-95 to psychiatric disease is an open question.   
  Mutations in the gene SAP102 are found in patients with X-linked mental 
retardation (Tarpey et al., 2004).  The mutations identified introduce premature stop 
codons within or before the third PDZ domain, and it is likely that this impairs the ability 
of SAP102 to interact with NMDAR and other proteins involved downstream of NMDAR 
signaling pathways (Tarpey et al., 2004; Zanni et al., 2009).  The disruption of the ability 
to bind NMDARs may lead to altered synaptic plasticity and explain the intellectual 
impairment observed in individuals with SAP102 mutations (Tarpey et al., 2004; Zanni et 
al., 2009).  Cuthbert et al. report the first characterization of Sap102 KO mice, and find 
that Sap102 mutant mice display cognitive deficits with a specific spatial learning deficit 
(Cuthbert et al., 2007).     
A variety of evidence implicates SAP97 in the etiology of ASD and SCZ.  Single 
nucleotide polymorphisms in SAP97 have been linked to an increased risk of SCZ in 
males, which supports the possible involvement of SAP97 gene variation in the 
susceptibility to SCZ and in the genetic basis for sex differences in the disorder (Uezato 
et al., 2012).  The human SAP97 gene resides in the chromosomal region 3q29, where 
multiple genome-wide analyses on copy number variations found an excess of 
microdeletions in SCZ (Kirov et al., 2011; Levinson et al., 2011; Kushima et al., 2016; 
Marshall et al., 2016).  A meta-analysis demonstrated the 3q29 deletion confers a 40-
fold increased risk for SCZ (Mulle, 2015).  Additionally, individuals with 3q29 
microdeletions spanning the SAP97 locus display autism and intellectual disability 
(Quintero-Rivera et al., 2010).  In another study of the expression levels of multiple 
postsynaptic density proteins, including PSD-95, PSD-93, and SAP102, the authors 
found a specific decrement in the level of SAP97 in post mortem frontal lobe from 
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schizophrenic patients (Toyooka et al., 2002).   SAP97 levels were decreased to less 
than half that of control levels, and concordantly, its binding partner GLUA1 was similarly 
decreased in the same brain region (Toyooka et al., 2002).   SAP97 is also the only 
member of the Dlg-MAGUK family that directly binds to the extreme C-terminus of the 
GLUA1 AMPAR, a subunit that promotes dendritic growth and patterned synaptic 
innervation (Zhou et al., 2008; Zhang et al., 2017). Thus, it is plausible that defects in 
these SAP97-dependent mechanisms contribute to a ASD and SCZ phenotype. 
However, unlike the other members of the Dlg-MAGUK family, the issue has been 
difficult to study because Sap97 knockout mice die a few days after birth from a 
craniofacial defect (Caruana and Bernstein, 2001).   
 
STATEMENT OF MOTIVATION AND HYPOTHESIS   
The goal of this thesis is to understand the direct contribution of SAP97 to 
neuropsychiatric disorders such as ASD and SCZ.  While mouse models for Psd-95, 
Psd-93, and Sap102 have been previously generated and characterized behaviorally, 
Sap97 null animals have been impossible study.  In Chapter 2, we determine whether 
Sap97 directly contributes to the pathophysiology of ASD and SCZ, and in what 
capacity, by generating mice that have a conditional knockout of Sap97 targeted to 
neurons using the Cre-loxP system.  Given the substantial evidence supporting the 
involvement of the Dlg-MAGUK family in neuropsychiatric disorders, we hypothesized 
that loss of Sap97 would contribute partially to the endophenotypes of ASD and/or SCZ-
like phenotype.  In order to test this hypothesis, we subjected the Sap97 conditional 
knockout mice to a battery of behavioral tests and biochemical studies to screen for an 
ASD or SCZ-like phenotype. We report that loss of Sap97 results in subtle sex-specific 
behavioral abnormalities and alters the expression of SCZ risk-associated gene 
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transcripts in the hippocampus.  This thesis works provides the first broad behavioral 
and transcriptomic characterization of Sap97 deficient animals, and provides a stepping-
stone for understanding the molecular mechanism by which SAP97 contributes for 
neuropsychiatric disorders.  
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CHAPTER 2: SAP97 REGULATES BEHAVIOR AND EXPRESSION OF 
SCHIZOPHRENIA RISK ENRICHED GENE SETS IN MOUSE HIPPOCAMPUS 
 
SUMMARY 
Synapse associated protein of 97KDa (SAP97) belongs to a family of scaffolding 
proteins, the membrane-associated guanylate kinases (MAGUKs), that are highly 
enriched in the postsynaptic density of synapses and play an important role in organizing 
protein complexes necessary for synaptic development and plasticity (Cai, 2006; Elias 
and Nicoll, 2007; Zhou et al., 2008; Chen et al., 2015; Zeng et al., 2016).  Large-scale 
genetic studies have implicated MAGUKs in neuropsychiatric disorders such as 
intellectual disability, autism spectrum disorders (ASD), and schizophrenia (SCZ), but 
knock-out mice have been impossible to study because the Sap97 null mice die soon 
after birth due to a craniofacial defect. We studied the transcriptomic and behavioral 
consequences of a brain-specific conditional knockout of Sap97 (SAP97-cKO).  RNA 
sequencing (RNAseq) from hippocampi from control and SAP97-cKO male animals 
identified 67 differentially expressed transcripts, which were specifically enriched for 
SCZ-related genes.  Subjecting SAP97-cKO mice to a battery of behavioral tests 
revealed an anxiety-like phenotype present in both male and female SAP97-cKO 
animals, as well as a male-specific cognitive deficit and female-specific motor learning 
deficit.  These data suggest that loss of SAP97 regulates behavior, and may contribute 
to some of the endophenotypes present in SCZ.  The SAP97-cKO mouse serves as a 
novel model system for interrogating aspects of the cellular and molecular defects 
underlying SCZ and other related neuropsychiatric disorders.  
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INTRODUCTION 
Intellectual disabilities and neuropsychiatric behavioral disorders affect about 
17.9% of individuals over their lifetime and interfere with the ability of people to 
experience a fulfilling and productive life (nimh.nih.gov).  Some of these disorders are 
clearly developmental.  For example, autism spectrum disorders (ASD) are 
characterized by impairments in social interaction and communication, and by restricted, 
repetitive behaviors and about 1% of children show signs and symptoms that lead to the 
diagnosis of ASD (Ebert and Greenberg, 2013; Uchino and Waga, 2013).  Schizophrenia 
(SCZ) is another mental disorder that is characterized by disordered thought processes 
and disturbed emotional responsiveness (Grabrucker et al., 2014).  The symptoms of 
SCZ usually appear during young adulthood, with an overall prevalence of about 0.7% 
(Fromer et al., 2014; Grabrucker et al., 2014).  Technological advances have brought 
unprecedented insights into the genetic architecture of these and many other 
neuropsychiatric disorders (De Rubeis et al., 2014; Fromer et al., 2014; Zhao et al., 
2014; Xing et al., 2016).  
Exome-sequencing technology has allowed us to systematically scan genes for 
de novo mutations at the single-base resolution, potentially offering insights into risk-
determining genes (Ghosh et al., 2013; Fromer et al., 2014).  Whole-exome sequencing 
results from patients with ASD or SCZ reveal significantly enriched copy number variant 
(CNV) mutations in the synaptic gene set (Fromer et al., 2014).  Among the most 
prevalent synaptic genes that have been uncovered in large-scale genomic studies have 
been alterations in the neurexins/neurolignins along with the PROSAP/SHANK family.  
Various genetically manipulated mice of these gene families recapitulate some of the 
behavioral features of ASD, SCZ, and intellectual disability (Peça et al., 2011; Wang et 
al., 2011b; Kouser et al., 2013; Han et al., 2014).  However, none of these models 
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completely phenocopy disease in humans, consistent with the polygenic origin of these 
disorders.  
Another important group of synaptic genes that has been implicated to be 
involved in ASD or SCZ is the Discs-large (Dlg) family of membrane associated 
guanylate kinases (MAGUKs) (Kristiansen et al., 2006; Funk et al., 2009; Feyder et al., 
2010; Xing et al., 2016; Winkler et al., 2017).  The Dlg family is the most 
comprehensively studied family of MAGUKs, and is comprised of PSD-95, PSD-93, 
SAP102, and SAP97.  They share a common domain structure comprised of three PDZ 
domains, along with an SH3 and GUK domain.  The Dlg-MAGUK family directly binds to 
many proteins in the postsynaptic density (i.e. glutamate receptor subunits, TARPS, and 
neurexin/neuroligin clusters), and regulates synaptic nanoscale structure and synaptic 
transmission (Bats et al., 2007; Mondin et al., 2011; Giannone et al., 2013) .  Mice with a 
targeted deletion of Psd-95, Psd-93, and Sap102 show a range of phenotypes also 
displayed by individuals with psychiatric disorders (Cuthbert et al., 2007; Feyder et al., 
2010; Winkler et al., 2017).   
A variety of evidence implicates SAP97 in the etiology of ASD and SCZ: 1) single 
nucleotide polymorphisms in SAP97 have been linked to an increased risk of 
schizophrenia in males (Uezato et al., 2012), 2) individuals with microdeletions spanning 
the SAP97 locus display autism and intellectual disability (Quintero-Rivera et al., 2010), 
and 3) a study of expression levels of multiple postsynaptic density proteins found a 
specific decrement in the level of SAP97 in post mortem frontal lobe from schizophrenic 
patients (Toyooka et al., 2002).   SAP97 is also the only member of the Dlg-MAGUK 
family that directly binds to the extreme C-terminus of the GLUA1 AMPA receptor 
(AMPAR), a subunit that promotes dendritic growth and patterned synaptic innervation 
(Zhou et al., 2008; Zhang et al., 2017). Thus, it is plausible that defects in these SAP97-
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dependent mechanisms contribute to a ASD and SCZ phenotype. While these findings 
advocate for the participation of SAP97 in the etiology of neuropsychiatric disorders, the 
issue has been difficult to study because Sap97 knockout mice die a few days after birth 
from a craniofacial defect (Caruana and Bernstein, 2001).   
In order to determine whether SAP97 directly contributes to the pathophysiology 
of ASD and SCZ, we generated mice that have a conditional knockout of Sap97 targeted 
to neurons using the Cre-loxP system.  We then subjected these mice to a battery of 
behavioral tests and biochemical studies to screen for an ASD or SCZ-like phenotype. 
Overall, our results suggest that loss of Sap97 results in sex-specific behavioral 
abnormalities as well as regulates transcripts of SCZ risk-related genes.   
 
 
MATERIALS AND METHODS 
 
Animals 
 
All animal procedures were approved by the Institutional Animal Care and Use 
Committee.  The Cre-loxP system was used to generate a Sap97 conditional knockout 
(cKO) mouse.  SAP97fl/- mice were generated as previously described (RRID: 
IMSR_JAX:013097).  Nestin-cre+/- mice on a C57Bl/6 background were purchased from 
Jackson Labs (stock number 003771, RRID: IMSR_JAX:003771). Nestin-cre+/-; 
SAP97fl/- mice were generated by crossing male Nestin-cre+/- with female SAP97fl/- 
mice.  Nestin-cre+/-; SAP97fl/- male mice were then crossed with female SAP97fl/- mice 
to generate Nestin-cre+/-; SAP97fl/fl (SAP97-cKO) and littermate control animals.  
Littermate control animals (genotype: Nes-cre+/-, SAP97fl/fl, and wild-type) were 
averaged and compared to cKO animals.  Genomic DNA was extracted from tail snips 
using the Phenolcholoroform acetate method to confirm genotypes.  The primers used 
for genotyping were as follows: Sap97 flox fwd- 
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AGAGTATGCTCTATGTGATGTTGTGTG rev-TAAGAAGGATCAACTGGCAAAGGTG; 
CRE fwd- ACCTGATGGACATGTTCAGG rev-CGAGTTGATAGCTGGCTGG 
 
Behavioral Experiments 
Open Field 
Assessment of general exploratory behavior and anxiety were evaluated using 
the open field paradigm.  Mice were placed in a white, opaque plexiglass box (40cm x 
40cm) and were given 15 minutes to explore the apparatus.  Exploratory locomotor 
activity (total distance traveled, average speed, and mean distance from border) was 
scored using the Any-MAZE tracking software (San Diego Instruments, San Diego, CA, 
RRID:SCR_014289).  
 
Elevated Plus Maze 
Assessment of anxiety-like behaviors was evaluated using an elevated plus 
maze (Coulbourn Instruments, Whitehall, PA).  The mouse was initially placed in the 
center “free zone”, and was allowed to freely explore the apparatus for the 5-minute trial 
time.  Time in the open arms versus the closed arms, as well as number of entries to 
these arms, was measured using the Any-MAZE tracking software.   
 
Accelerating Rotarod 
Assessment of motor learning and motor coordination was evaluated using the 
accelerating rotarod (Ugo Basile, Varese, Italy).  The starting acceleration was 4 rpm, 
and accelerated to 40 rpm over a 5-minute trial time.  Mice underwent 3 trials per day for 
4 consecutive days, for a total of 12 trials.  Latency to fall from the rod was manually 
measured and compared across the 4 days.   
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Novel Object Recognition (NOR) 
Assessment of cognition was evaluated using the NOR paradigm.  The testing 
apparatus was a white, opaque plexiglass box (40cm x 40cm).  On day 1, mice were 
habituated to the testing apparatus for 15 minutes.  On day 2, the mice were 
reintroduced to the testing apparatus and allowed to explore two identical objects equally 
spaced from the walls of the apparatus (objects A and A’) for 5 minutes and the animal 
was then removed.  Any-MAZE tracking software was used to measure the time spent 
investigating each object, and a preference index (PI) was calculated by dividing time 
spent investigating A’ by time spent investigating A (A’/A).  One hour later after identical 
object exploration, the mouse was placed back in the testing apparatus where one of the 
identical objects had been replaced with a novel object that differed in shape, color, and 
texture (object B).  Again, the mouse was given 5 minutes to explore the two objects, 
and preference for the novel object was calculated by dividing time spent investigating B 
by time spent investigating A (B/A).  Significant preference for the novel object was 
assessed by comparing the PI from the training phase to the PI from the testing phase.   
 
Three Chambered Social Choice 
Assessment of sociability was evaluated using the standard three-chambered 
social choice paradigm.  A white, opaque plexiglass rectangular box was used, with 
three partitions (each 20cm x 40cm).  The mouse was first given 5 minutes to habituate 
to the empty apparatus.  After habituation, into the left and right compartments was 
placed either with an inanimate object (non-social zone) or an age and sex-matched 
C57Bl/6 mouse (social zone).  The object and mouse were placed under clear, 
plexiglass cylinders with perforations to allow odor detection.  During the testing phase, 
the test mouse was allowed five minutes to explore either zone.  Time in each zone was 
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measured using the Any-MAZE tracking software and sniffing time of either the 
inanimate or social target was manually scored.  Social zone preference was calculated 
by dividing social zone time by total zone exploration time, and social sniffing preference 
was calculated by dividing time spent sniffing the social target by total sniffing time.  
 
Cued Fear Conditioning 
Assessment of amygdala dependent fear learning was evaluated using the cued 
fear conditioning paradigm.  Fear conditioning paradigms pair an emotionally neutral 
stimulus, such as light/tone (conditioned stimulus or CS) with an aversive stimulus, such 
as footshock (unconditioned stimulus or US), leading to the expression of a threat 
response (freezing) to presentation of the neutral CS alone.  For these experiments, the 
context was altered between training (context A) and testing (context B) to isolate the 
light/tone (CS) cued response from the hippocampal dependent contextual response. 
The cued fear conditioning paradigm used in this study was modified from 
experiments described in (Newton et al., 2004; Wolff et al., 2014). The CS consisted of 
simultaneous auditory (75dB, white noise, 20s) and light stimuli (yellow light pulses, 20s, 
flickering at 4 Hz) generated by built in audio and light stimuli generators (Med 
Associates, Fairfax, VT). The US consisted of a footshock (1.05mA, 1.5s) delivered 
through the metal grid floor. During CS-US pairings, the US was delivered immediately 
following the cessation of the CS.  On day 1 of this paradigm, animals underwent fear 
conditioning training in context A, a rectangular conditioning chamber (21.6 cm × 17.8 
cm × 12.7 cm) with Plexiglas and metal walls, and a metal grid floor (Med Associates, 
Fairfax, VT). Animals were allowed to freely explore the chamber for 1 min before 
experiencing 3 CS-US pairings (60s interstimulus interval). 
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One min after the final CS-US pairing (5 min total), mice were removed from 
context A and placed back in their home cage.  Twenty-four hours later (day 2) animals 
underwent behavioral testing to measure freezing in context B, a custom made triangular 
conditioning chamber with black striped Plexiglas walls and a smooth, opaque black 
plastic floor, scented with organic vanilla extract. Mice were allowed to freely explore the 
chamber for 1 min before experiencing 3 presentations of the CS alone (60s, 
interstimulus interval). Again, animals were removed from context B after a total of 5min. 
During testing, freezing behavior was scan sampled every 5th second from the onset of 
the first CS presentation to the end of the trial (4 min total). Freezing was defined as a 
total lack of movement aside from respiration at the instant of every 5th second. The 
total number of freezing spells was then divided by total observations to generate a 
freezing percentage per animal.  
 
Biochemistry 
Mice were anesthetized with a pentobarbital solution and decapitated.  The brain 
was removed, and each hemisphere of the cerebellum, cerebral cortex, and 
hippocampus was dissected.  One hemisphere was rapidly transferred to a mortar and 
pestle prechilled on dry ice, and ground into a fine powder to be processed for RNA 
extraction by the RNeasy mini kit (Qiagen, Catalogue #74134) according to the 
manufacturer’s instructions.  Once RNA extraction was complete, conversion to cDNA 
was done using the iScript Supermix (Bio-Rad, Catalogue #1708841, Hercules, CA).  
The other hemisphere was transferred to a dounce prechilled on ice, and lysed in 1% 
Triton-X lysis buffer with protease and phosphatase inhibitors for generation of protein 
lysates.   
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Antibodies 
 
The following antibodies were used in this study as follows: immunoblotting of 
SAP97 (Thermo Fisher Scientific, catalogue # PA1-741, RRID:AB_2092020); 
immunoblotting of PSD95 (NeuroMab, catalogue # 75-348, RRID:AB_2315909); 
immunoblotting of PSD93 (NeuroMab, catalogue # 75-284, RRID:AB_11001825); 
immunoblotting of SAP102 (NeuroMab, catalogue # 75-058, RRID:AB_2261666); 
immunoblotting beta-actin (Cell Signaling Technology, catalogue # 3700 (mouse), 
RRID:AB_2242334 or Sigma-Aldrich, catalogue # A2066 (rabbit), RRID:AB_476693).  
Secondary antibodies for immunoblots (IRDye) were purchased from Li-COR (Catalogue 
# 925-32210, RRID: AB_2687825 and Catalogue # 925-68021, RRID: AB_2713919). 
 
Western Blot 
Western blot was performed according to standard procedures (David and Kalb, 
2005; Kim et al., 2005; Mojsilovic-Petrovic, 2006). 
 
Quantitative PCR 
Quantitative real-time PCR (qPCR) was carried out as previously described using 
the delta delta Ct method to calculate relative gene expression levels (Livak and 
Schmittgen, 2001).  Ribosomal S17 and S18 (RS17, RS18) were used as reference 
genes.  Each reaction consisted of cDNA, primers, and Power SYBR Green PCR Master 
Mix (Applied Biosystems, Catalogue # 4367659, Waltham, MA) with a total 25uL 
reaction volume.  Melting curve analysis of the target sequences showed that all primers 
used in this study generated amplification of a single peak, without primer-dimer 
artifacts.  Primer and cDNA concentrations were optimized prior to use in qPCR 
experiments.  Each qPCR experiment consisted of 4-6 biological replicates, as well as 
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three technical replicates per sample.  The primers used for qPCR included: Glua1 fwd- 
CCCTGAGAGGTCCCGTAAAC rev- GCTCAGAGCACTGGTCTTGT; Glua3 fwd- 
CCATGCTCTTGTCAGCTTCG rev- AGTCCACCTATGCTGATGGT; Glua4 fwd- 
TGAATGAACAAGGCCTCTTGGA rev- AGGCACTCGTCTTGTCCTTG; Nrcam fwd- 
AAGACCCGCTGGACTTTGAA rev- GGCTTGCCATTGCCTTCTTA; Huwe1 fwd- 
GTTGGGATTTCCCACCAGGA rev- CAGTCTGCAGGAGCTTCAGT; Pten fwd- 
CCTGCAGAAAGACTTGAAGGTG rev- CTGTGCAACTCTGCAGTTAAA; Adam10 fwd- 
GGCTGGGAGGTCAGTATGGA rev- CTCGTGTGAGACTGCTCGTT; Was fwd- 
TCAGCTGAACAAGACCCCTG rev- CATGCATCAGGGCACCTACT; Erbb4 fwd- 
ACCCAGGGGTGTAACGGT rev- TGGTAAAGTGGAATGGCCCG; Sema4C fwd- 
GGTGGCCGGAGTCAAACG rev- TTCAGTCCAGCAGCCCTCTTT; Kcna3 fwd- 
TCCGAAAAGCCCGGAGTAAC rev- CTGTGGAGTTGCCCGTTTTG; Kcna4 fwd- 
CACTTGCTGGGAATGGTGAAGT rev- GAGAAGGTGGTAGACGCAGT; Kcna5 fwd- 
TAGGACACTGGCTGACCCAT rev- ACGCACAAGCAGCTCAAAAG; Gng13 fwd- 
TTGCTGTCTCCTCCAAAACCTC rev- TCCCTCTTGAAGGCCAGTTG; Fzd7 fwd- 
AGAACCTCGGCTACAACGTG rev- ACCGAACAAAGGAAGAACTGC; Dlgap4 fwd- 
TTTGCTTCTCTGCCCGATCC rev- TGATGAACATTGCTTCAAGAGC; Ctnna1 fwd- 
CAGTTCGCTGCAGAAATGAC rev- ACCTGTGTAACAAGAGGCTCC; Calm3 fwd- 
GAGTAACCTCGATCCCCGAG rev- GAAGGCTTCCTTGAACTCTGC; Kcnc1 fwd- 
CTACGCGCGGTATGTGGC rev- TCGGTCTTGTTCACGATGGG; Axin2 fwd- 
CAGCCCAAGAACCGGGAAAT rev- AGCCTCCTCTCTTTTACAGCA; Lef1 fwd- 
GTCGACTTCAGGTGGTAAGAGA rev- TGCTGTCAGTGTTCCTTGGG; β-catenin fwd- 
GTCAGTGCAGGAGGCCG rev- CAGGTCAGCTTGAGTAGCCA; Runx2 fwd- 
GCCTTCAAGGTTGTAGCCCT rev- GTTCTCATCATTCCCGGCCA; Kalirin fwd- 
GAGTTCAGGGTGGGATGACG rev- CCATCATTCCGAAAAGATCCTCG; Nudel1 fwd- 
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TTTCTTCCATAAAGGGGCAGT rev- ACACTGAGAGGCAGCATACC; Fez1 fwd- 
ATCCCAGGCAGATTCAGTCC rev- TCTCAGCCCTTCATAGGACCA; Tnik fwd- 
TGCCGAACATGAGCAGGAAT rev- AGTAGAGCTTGCTCATGCAGT; Citron fwd- 
GAAGGAACACAAGGCCGAGA rev- TCCAGGTCGTTGAGCTTGTC; Girdin fwd- 
CACCACCTACTGCTGGTAGC rev- CTTTTCTCTCCCAGGCCCAC; Grb2 fwd- 
CAGTGGAATTAAAAAGGGTGGCA rev- GGGAATCTTCCCTGCTGAAGAG; S18 fwd- 
CAGCTCCAAGCGTTCCTGG rev-GGCCTTCAATTACAGTCGTCTTC; S17 fwd- 
GATTCAGAGAGGGCCTGTGAG rev-CTGAGACCTCAGGAACGTAGT 
 
RNA Sequencing 
RNA was isolated from four control and four SAP97-cKO male hippocampi, 
quality evaluated by Bioanalyzer 2100 (Agilent Technologies, Santa Clara, CA), and 
sequenced with an Illumina HiSeq 4000 High-Throughput Sequencing System. The 
RNA-seq reads were aligned to the mouse genome mm10.GRCm38.p5 using STAR 
version 2.5.3a (Dobin et al., 2012). Next, normalization and quantification were 
performed with the PORT version 0.8.2a-beta pipeline 
(http://github.com/itmat/Normalization) which first removes reads that map to ribosomal 
RNA sequences or mitochondrial DNA and then uses a read re-sampling strategy for 
normalization to account for batch effects and differences in sequencing depth among 
the samples. After the normalization procedure, the gene level quantification was done 
by PORT with respect to the Ensemblv90 annotation. The normalized count of reads 
mapping to exon 10 of Sap97 showed almost 30-fold reduction from an average of 242 
in the control samples to an average of 8 in the SAP97-cKO samples affirming the 
efficacy of the knockdown procedure. The differential expression analysis was 
performed using the R Bioconductor package limma-voom (Law et al., 2014; Ritchie et 
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al., 2015). The top 566 genes with FDR < 0.5 and fold-change of greater than 1.6 were 
used for general pathway enrichment analyses, which were performed using Ingenuity 
IPA.  
 
Analysis of overlap between differentially expressed genes and risk-associated 
disease genes 
The significance of overlap between the set of differentially expressed genes 
(DEGs) and risk-associated ASD, SCZ, and other neuronal disorder genes was 
analyzed using non-parametric analysis.  The ASD gene list was chosen from research 
by Silvia De Rubeis et al. (De Rubeis, et al., 2014), while the SCZ and ataxia gene lists 
were chosen from online resources (szdb.org, genedx.com). Details of the lists chosen 
and overlap analysis are discussed in results section.  The mean and variance of the 
corresponding hypergeometric distribution were calculated. The p value of the 
significance of the overlap was estimated using the hypergeometric probability test.  
 
Statistics 
Data were analyzed using Prism (GraphPad Software, La Jolla, CA, 
RRID:SCR_015807).  Significant differences within groups were determined using either 
Student’s t-test, one-way ANOVA followed by Tukey’s test for multiple comparisons, or 
repeated-measures two-way ANOVA followed by Tukey’s test for multiple comparisons.  
For all tests except for RNAseq, the significance threshold was set to p<0.05.  The 
significance threshold for DEGs in the RNAseq experiment was set to FDR <0.25.   
 
RESULTS 
Targeted deletion of SAP97 to neurons 
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Global Sap97 knockout mice have been generated, but die soon after birth due 
to a craniofacial defect.  In order to study the effect of loss of Sap97 on neuronal 
development and behavior, we conditionally knocked out Sap97 by crossing Nestin-cre 
mice with Sap97 floxed mice (see Methods).  SAP97-cKO mice were born at Mendelian 
ratios and were grossly normal.  At two months of age, we harvested tissue from the 
cerebellum, hippocampus, and cortex from control and SAP97-cKO animals of both 
sexes and prepared protein lysates for western blot analysis. In all three brain regions, 
the abundance of SAP97 was significantly reduced (Cerebellum: Ctrl 3.998 ± 0.9833, 
n=4; SAP97-cKO 1.373 ± 0.348, n=5, p=0.0279; Hippocampus: Ctrl 4.252 ± 0.6751, 
n=5; SAP97-cKO 1.215 ± 0.4314, n=5, p=0.0053; Cortex: Ctrl 0.287 ± 0.08557, n=5; 
SAP97-cKO 0.06179 ± 0.01072, n=5, p=0.0311), indicating that we successfully 
generated cKO animals (Figure 1A-D).  Additionally, in order to ensure male and female 
animals had comparable expression of SAP97, we harvested tissue from the 
cerebellum, hippocampus, and cortex from male and female C57Bl/6 animals and 
prepared protein lysates for western blot analysis.  In all three brain regions, the 
abundance of SAP97 was not significantly different between male and female animals 
(Cerebellum: Male 0.3029 ± 0.03097, n=4; Female 0.3162 ± 0.03791, n=4; 
Hippocampus: Male 0.3296 ± 0.03764, n=4; Female 0.3135 ± 0.03483, n=4; Cortex: 
Male 0.3272 ± 0.0134, n=4; Female 0.257 ± 0.04237, n=4) (Figure 1E-F).   
 
No apparent compensation by other DLG-MAGUK family members 
Previous work shows that the Dlg-MAGUKs (PSD-95, PSD-93, SAP102, and 
SAP97) can have redundant functions in electrophysiological assays.  In order to 
examine whether loss of SAP97 led to compensatory changes in the abundance of the 
other Dlg-MAGUK family members, we measured total protein levels in the cerebellum, 
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hippocampus, and cortex.  There was no significant difference in the abundance of any 
other Dlg-MAGUK at the protein level in control versus SAP97-cKO male or female 
animals (Figure 2).  These data suggest that if members of the Dlg-MAGUK family 
compensate for the lack of SAP97, they do so without a change in overall abundance.  
 
No changes in gene expression level of known SAP97 binding partners or 
interactors 
SAP97 is a scaffolding protein that allows for a large number of protein-protein 
interactions.  Thus, the absence of SAP97 could potentially affect the expression level of 
numerous proteins.  To determine whether loss of Sap97 contributes to changes in 
expression levels of other identified members of the postsynaptic density, we conducted 
a directed qPCR screen.  We measured mRNA levels firstly of all AMPAR subunits, as 
SAP97 is known to be the only Dlg-MAGUK to directly bind GLUA1.  mRNA levels of 
Glua1, Glua3, and Glua4 remained unchanged in the three brain regions that were 
probed (cerebellum, hippocampus, and cortex) (Figure 3A).  Results from Glua2 were 
highly variable and thus removed from the study.   
We next sought to determine whether the levels of other genes known to interact 
with Sap97 were affected by loss of Sap97.  We measured mRNA levels of 16 genes in 
the hippocampus.  From our selection of 16 genes, we observed no differences in the 
mRNA expression level between control and SAP97-cKO animals (Figure 3B).  We also 
measured mRNA levels of 4 of these 16 genes in the cerebellum and cortex and 
observed no differences in the mRNA expression level between control and SAP97-cKO 
animals (Figure 3B).  These results would suggest that the abundance of genes from our 
selection is not significantly regulated by Sap97 expression.  
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SAP97 also shares direct and indirect binding partners with DISC1, a gene with 
strong association with neuropsychiatric disorders.  Our lab has previously shown that 
SAP97 and DISC1 contribute to maintaining Wnt/β-catenin signaling within a 
homeostatic range.  In order to address whether loss of Sap97 has an effect on the 
Wnt/β-catenin pathway in the SAP97-cKO mice, we measured mRNA levels of 4 
pathway-related genes in the hippocampus, and 2 of these genes in the cortex.  In both 
brain regions, we observed no differences in the mRNA expression level between 
control and SAP97-cKO animals (Figure 3C).  We also measured mRNA levels of 7 
Disc1 pathway-related genes in the cortex and observed no differences in expression 
between control and SAP97-cKO animals (Figure 3D).  These results would suggest that 
the abundance of genes from our selection is not significantly regulated by Sap97 
expression.   
 
Identification of SAP97-regulated transcripts in the hippocampus 
Given that we observed no group differences in our directed qPCR screen, we 
sought a broader, unbiased approach by performing RNAseq analysis on hippocampi 
from SAP97-cKO and control mice (n = 4 per group).  For each animal, we verified the 
presence or absence of SAP97 by western blot on brain tissue before submitting 
hippocampal samples for sequencing.   
A total of 66 genes were found to be significantly downregulated in the SAP97-
cKO animals as compared to control hippocampi (FDR < 0.25) (Figure 4B, Table 1).  In 
contrast, only one gene was upregulated in the hippocampi of SAP97-cKO animals as 
compared to control hippocampi.  Gene ontology analysis of the DEGs revealed 
enrichment for numerous cellular and molecular functional categories, including those 
related to “Cell Morphology,” “Cellular Development,” and “Cell-To-Cell Signaling and 
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Interaction” (Table 2A-B).  Additionally, the top enriched ID Associated Network 
Functions included “Cellular Development, Cellular Growth and Proliferation, 
Hematological System Development and Function,” and “Developmental Disorder, 
Embryonic Development, Organ Development” (Table 2C).  Gene ontology terms to 
describe gene products known to be associated with ASD or the neurexin-neuroligin-
SHANK complex in mice frequently include “Cell Communication” and “Nervous System 
Development”, which overlaps with the findings in our RNAseq study (Patel et al., 2015).  
Previous studies that have conducted RNAseq on SCZ patients and performed gene 
ontology analysis on the resulting DEGs have identified regulation of the actin 
cytoskeleton as a key pathway (Zhao et al., 2014).  While the actin cytoskeleton was not 
directly implicated by our RNAseq study, it is essential for many of the gene ontology 
analysis terms listed in our data set.  As proper arrangement of the actin cytoskeleton is 
essential for neuronal cell maturation and migration, neurite outgrowth, and maintenance 
of synaptic density and plasticity, dysregulation of these pathways in the nervous system 
could have severe consequences in psychiatric disorders such as SCZ. 
 
Schizophrenia risk enrichment in DEG set 
In order to determine whether the DEG set had a significant overlap with genes 
implicated in psychiatric disorders such as ASD and SCZ, we compared our DEG set 
with disease-related gene databases.  For determining overlap with ASD-related genes, 
we used the gene set previously generated from the transmission and de novo 
association test (TADA), which consists of 107 genes.  When we matched our DEG list 
to the TADA ASD gene list, we did not find the match percentage to be significant based 
on the hypergeometric distribution (Distribution mean = 0.30, standard deviation = 0.30; 
SAP97-cKO DEG 0.0) (Figure 4C).  We next chose to compare our DEG list to SCZ risk-
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related genes found from SZDB: A Database for Schizophrenia Genetic Research 
(szdb.org).  The distilled list of genes from this database gives a score for each gene 
based on criteria such as convergent functional genomics, copy number variation, 
differential expression, genome wide association study, and linkage and association 
studies.  The more categories a certain gene is implicated in, the higher the score for 
that gene.  Based on this model, we chose the top 1,000 genes from this database to 
match to our SAP97-cKO DEG list.  Interestingly, we found the SAP97-cKO DEG list to 
have a significant amount of overlap to the SZDB list based on the hypergeometric test 
(Distribution mean = 2.79, standard deviation = 1.63; SAP97-cKO DEG 13.43, 
p=0.0018) (Figure 4C).  Finally, we matched our SAP97-cKO DEG list to ataxia risk-
related genes as a negative control, as ataxia is not classified as a neuropsychiatric 
disorder and SAP97 has not previously been implicated in ataxia.  We used a list of 
ataxia risk-related genes compiled from GeneDx, whose clinical team compiled using 
multiple sources, including Online Mendelian Inheritance in Man (OMIM), Human Gene 
Mutation Database (HGMD), and Human Phenotype Ontology (HPO) terms.  The total 
number of genes in this list was 993, which would also allow us to control for the size of 
the SCZ gene list used.  When we compared our SAP97-cKO DEG list to the GeneDx 
ataxia gene set, we found no significant match percentage (Distribution mean = 2.77, 
standard deviation = 2.65; SAP97-cKO DEG 4.48) (Figure 4C).  Together, these results 
suggest that SAP97-cKO DEGs are specifically enriched for SCZ risk-related genes.   
 
Behavioral analysis of SAP97-cKO mice 
Next, we performed a battery of behavioral tests to screen for behavioral deficits 
in the SAP97-cKO mice.   
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Anxiety-like phenotype in SAP97-cKO mice 
We first performed the open field test to examine general ambulation and center 
exploration behavior.  In the males, we observed no change in the total distance traveled 
(Ctrl 64.8 ± 2.102, n = 29; SAP97-cKO 61.76 ± 3.763, n = 19) (Figure 5A) or the speed 
of the animals (Ctrl 0.07214 ± 0.002259, n = 29; SAP97-cKO 0.06847 ± 0.004183, n = 
19) (Figure 5B), but saw a reduction in the distance from the border (Ctrl 0.06531 ± 
0.001558, n = 29; SAP97-cKO 0.05939 ± 0.00237, n = 19, p=0.0346) (Figure 5C).  This 
indicates that the male SAP97-cKO mice stay closer to the perimeter of the apparatus as 
compared to littermate control, implying that while SAP97-cKO animals do not have a 
basic impairment in movement, they may have an anxiety-like phenotype.  Female 
SAP97-cKO animals exhibited decreases in total distance traveled (Ctrl 64.39 ± 3.495, n 
= 24; SAP97-cKO 52.1 ± 4.519, n = 12, p=0.0446) (Figure 5A) and speed (Ctrl 0.0717 ± 
0.004071, n = 24; SAP97-cKO 0.058 ± 0.005053, n = 12, p=0.0497) (Figure 5B) in 
addition to a reduction in distance from the border (Ctrl 0.06063 ± 0.001486, n = 24; 
SAP97-cKO 0.05369 ± 0.001995, n = 12, p=0.0088) (Figure 5C).  Overall, these 
observations indicate an anxiety-like phenotype present in both male and female 
SAP97-cKO animals.   
Anxiety is a common comorbidity associated with various psychiatric disorders.  
In order to further gauge whether SAP97-cKO mice had alterations in anxiety-like 
behavior, we performed the standard elevated plus maze.  When comparing time spent 
in open arms versus the closed arms, we saw no significant differences between 
genotypes in both males (open arms: Ctrl 69.75 ± 4.098, n = 33; SAP97-cKO 62.47 ± 
9.331, n = 15; closed arms: Ctrl 160.8 ± 5.339, n = 33; SAP97-cKO 179.3 ± 8.893, n = 
15) and females (open arms: Ctrl 68.17 ± 6.734, n = 20; SAP97-cKO 64.85 ± 7.72, n = 
13; closed arms: Ctrl 156.6 ± 8.515, n = 20; SAP97-cKO 172.5 ± 8.559, n = 13) (Figure 
43 
 
6A).  Likewise, the number of entries into the open versus closed arms was similar 
between genotypes of both sexes (Figure 6B).  Total distance traveled in the maze was 
also measured and compared between Ctrl and SAP97-cKO animals to ensure no 
significant differences in overall exploration of the maze (Figure 6C).  Together with the 
open field results, these observations indicate an anxiety-like phenotype in both male 
and female SAP97-cKO animals that is particular to specific behavioral tasks.  
 
No changes in cued fear conditioning behavior in male SAP97-cKO mice 
Amygdala circuitry is key for regulating anxiety-like responses in mice, and 
amygdala neuronal activity has been shown to be increased in the open field paradigm 
(Wang et al., 2011a).  Given the observed increase in anxiety-like behavior in the 
SAP97-cKO mice and the wide expression pattern of Sap97, we were interested to know 
whether dysfunction in the amygdala might contribute to these observations. We decided 
to test the mice in the standard cued fear-conditioning paradigm (see Methods), which is 
thought to be an amygdala specific behavior.  Both control and SAP97-cKO male and 
female mice exhibited normal freezing behavior (Male: Ctrl 46.96 ± 3.652, n = 15; 
SAP97-cKO 58.53 ± 6.029, n = 10; Female: Ctrl 35.89 ± 5.249, n=3; SAP97-cKO 40.1 ± 
3.932, n=4) (Figure 7).  These results suggest that the SAP97-cKO mice have no deficit 
in cued fear conditioning behavior and the described anxiety phenotype may be 
independent of amygdala circuitry.  
 
Male-specific cognitive deficit in SAP97-cKO mice 
Cognitive deficits are another endophenotype observed in various psychiatric 
conditions.  Given that cognitive deficits are also present in several mouse models of 
human psychiatric disorders, we examined SAP97-cKO mice for this behavior.  The 
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novel object recognition task is a standard test for cognition that measures ability to 
recall an object previously observed, as indicated by preference for a novel object (see 
Methods).  During the training phase of this task, we observed no significant differences 
between the ratio of time spent investigating the two identical objects A and A’ for both 
males and females (Male: Ctrl 1.364 ± 0.1438, n = 29; SAP97-cKO 1.441 ± 0.1578, n = 
15; Female: Ctrl 1.3 ± 0.2506, n = 22; SAP97-cKO 1.301 ± 0.2775, n = 10) indicating 
that the animals had no prior bias.  During the testing phase, control male mice 
displayed a marked increase in the preference index for the novel object, while SAP97-
cKO male mice showed no significant increase in novel object preference index (Ctrl A-A 
1.364, Ctrl A-B 2.457; SAP97-cKO A-A 1.441, SAP97-cKO A-B 1.941, F (3, 79) = 5.311, 
p=0.0022) (Figure 8).  When we examined this behavior in the females, we observed a 
trending, but not significant, increase in preference index for the novel object in both 
control and SAP97-cKO animals (Ctrl A-A 1.3, Ctrl A-B 2.255; SAP97-cKO A-A 1.301, 
SAP97-cKO A-B 2.575, F (3, 57) = 2.59, p=0.0616) (Figure 8).  These findings suggest a 
male-specific cognitive deficit in the SAP97-cKO animals.   
 
Female-specific motor learning deficit in SAP97-cKO mice 
Alterations in motor learning and motor coordination have also been observed in 
mouse models of ASD.  In order to determine whether this behavioral change is present 
in the SAP97-cKO mice, we performed the standard rotarod task (see Methods).  
Analysis of both sexes showed significant time effects (Male: F (3, 6) = 12.31, p=0.0057; 
Female: F (3, 6) = 9.126, p=0.0118), while only female animals showed a trend for 
genotype effects and significant time and genotype interaction effects (genotype effect: F 
(1, 2) = 11.53, p=0.0769; time x genotype effect: F (3, 6) = 5.099, p=0.0434) (Figure 9A).  
Control animals of both sexes showed a significant increase in latency to fall from the 
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rod from day 1 to day 4 (Male: Day 1 157.5 ± 19.12, Day 4 211.1 ± 2.074, n = 30, 
p=0.0010; Female: Day 1 171.6 ± 16.53, Day 4 237.3 ± 3.439, n = 21, p=0.0021), 
indicating learning of the task (Figure 9A-B).  However, while male SAP97-cKO mice 
showed no learning impairment (Day 1 154.4 ± 16.64, Day 4 229.4 ± 0.8372, n = 18, 
p=0.0002), female SAP97-cKO mice showed no significant learning over the timecourse 
of this task (Day 1 186 ± 7.927, Day 4 213.3 ± 9.988, n = 16) (Figure 9A-B).  In order to 
determine whether this female motor learning impairment was dependent on age, we 
tested a subset of aged animals (8-9 months) on the rotarod task.  While both aged 
control and SAP97-cKO female animals did not display significant learning over the 4-
day task (Control: Day 1 146.6 ± 15.06, Day 4 185.3 ± 3.153, n = 7; SAP97-cKO: Day 1 
95.07 ± 8.834, Day 4 129.2 ± 7.136, n = 5), female SAP97-cKO animals performed 
worse overall as compared to littermate controls.  These results suggest that there is a 
female-specific motor learning deficit present in the SAP97-cKO mice that persists with 
age.   
 
No social deficits present in SAP97-cKO mice 
Problems with socialization are often seen in patients with ASD, and many 
genetic mouse models of ASD have been able to mimic this behavioral deficit.  We 
looked for this endophenotype in the SAP97-cKO mice using the three-chambered social 
choice paradigm (see Methods).  During the testing phase of this paradigm, we 
measured preference for the social target zone versus the nonsocial target zone.  
Control and SAP97-cKO animals of both sexes exhibited a strong preference for 
spending time in the social target zone (Male: Ctrl-Nonsocial 0.334, Ctrl-Social 0.666, n 
= 15; SAP97-cKO-Nonsocial 0.4164, SAP97-cKO-Social 0.5836, n = 11, F (3, 48) = 24.67, 
p<0.0001; Female: Ctrl-Nonsocial 0.3641, Ctrl-Social 0.6359, n = 8; SAP97-cKO-
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Nonsocial 0.3045, SAP97-cKO-Social 0.6955, n = 8, F (3, 20) = 14.53, p<0.0001) (Figure 
10A).  Manual scoring of sniffing preference for the social target versus the nonsocial 
target was also measured for the male animals.  Control and SAP97-cKO male animals 
also exhibited a strong preference for sniffing/investigating the social target (Ctrl-
Nonsocial 0.2663, Ctrl-Social 0.7337, n = 8; SAP97-cKO-Nonsocial 0.3513, SAP97-
cKO-Social 0.6487, n = 8; F (3,28) = 54.84, p<0.0001).  These results suggest no social 
deficit in the SAP97-cKO mice.   
 
DISCUSSION 
SAP97 is a member of the Dlg-MAGUK family that has repeatedly been 
implicated in neuropsychiatric disorders (Quintero-Rivera et al., 2010; Uezato et al., 
2012; 2015; Xing et al., 2016), although its direct role in contributing to pathology has 
been unexplored.  We generated and studied mice that were null for Sap97 in the 
nervous system and make three principal observations.  First, there are no 
compensatory changes in expression levels of other Dlg-MAGUKS or AMPARs in the 
SAP97-cKO versus controls.  Second, loss of Sap97 is associated with changes in gene 
transcripts related to SCZ.  And third, SAP97-cKO animals of both sexes display an 
anxiety-like phenotype, as well as a male-specific cognitive deficit and female-specific 
motor learning deficit.  Our results argue that Sap97 is required for normal brain function 
and its absence leads to specific behavioral deficits and transcriptomic changes 
associated with SCZ. 
 
ASD and SCZ as polygenic disorders  
Investigations of ASD, SCZ, and other related psychiatric disorders indicate a 
highly polygenic architecture with small effect sizes of each implicated risk variant.  
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Mouse modeling of these disorders by targeting one such risk variant typically 
demonstrates a moderate, or incomplete manifestation of the human disorder.  This is 
well illustrated by human and mouse studies of the PROSAP/SHANK family member 
SHANK3.  Human genetic studies link mutations in SHANK3 to a broad range of 
neuropsychiatric disorders.  For example, deletions of exons 1-9 or exons 1-17 of 
SHANK3 have been found in patients exhibiting severe language delay and significant 
intellectual disability.  Mice generated to mimic these deletions were generated by Peca 
et al. and the main behavioral effects were repetitive grooming and deficits in social 
interaction (Peça et al., 2011).  Jiang et al. used a different targeting strategy to mimic 
the human deletions and the mice displayed repetitive behaviors, deficits in social 
interaction, abnormal ultrasonic communication patterns and learning and memory 
deficits (Jiang and Ehlers, 2013).  In a second well-studied family, affected individuals 
displayed ASD-features and this was linked to a deletion of SHANK3 exon 21 (an exon 
that included the Homer binding domain).  Mice generated to mimic this genetic lesion 
were created by Kouser and Speed et al. and ~2.5 month old animals exhibit defects in 
spatial learning and memory, motor-coordination deficits, hypersensitivity to heat, 
novelty avoidance, but minimal social abnormalities and no repetitive grooming behavior 
(Kouser et al., 2013).  Together, this work demonstrates that creating a mouse with a 
genetic lesion that closely mimics, or is identical, to the gene defect in humans with 
neuropsychiatric disease only partially recapitulates the human behavioral phenotypes.  
This disparity between genetic lesions associated with psychiatric phenotypes 
and mice created to mimic the human condition also extends to the Dlg-MAGUK family.  
Nonsynonymous missense mutations in the Dlg-MAGUK family members have been 
found in ASD and SCZ patients, and decreased protein expression of PSD-95, PSD-93, 
and SAP97 has been observed in the cortex of postmortem SCZ patients.  To model 
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with in mice, null alleles of Psd-95, Psd-93, and Sap102 have been created—Psd-95 
and Sap102 knockout animals share spatial learning memory deficits (Migaud et al., 
1998; Cuthbert et al., 2007), while animals null for Psd-95 or Psd-93 share a hyper-
social phenotype (Winkler et al., 2017).  Psd-95 and Sap102 knockout animals display a 
mild, and Psd-93 knockout animals display a severe, motor function defect (Cuthbert et 
al., 2007; Winkler et al., 2017).  The Psd-95 null mouse has been the most extensively 
investigated animal.  Feyder et al. characterized the Psd-95 knockout mice and the mice 
exhibit increased repetitive behaviors, abnormal communication, hyper-social behavior, 
impaired motor coordination, and increased stress-reactivity and anxiety-related 
responses (Feyder et al., 2010).  The extent to which the Psd-95 null mice faithfully 
report on the contribution of PSD-95 to psychiatric disease is an open question.   
 
SAP97 splice variants and their differing roles in the nervous system 
SAP97 has wide molecular diversity, which is created by extensive alternative 
splicing.  The two most well-studied Sap97 splice variants are Sap97α and Sap97β.  In 
Sap97α, the prototypic N-terminal L27 domain is replaced with a putative palmitoylation 
motif.  Overexpression of SAP97α (but not SAP97β) was shown to enhance the synaptic 
levels of AMPARs and to compensate for the shRNA-mediated loss of PSD-95 in 
organotypic slices (Waites et al., 2009). SAP97 isoform-specific biology may also extend 
into human SCZ data.  Uezato and colleagues identified a new SAP97 splicing variant 
that is transcribed from a previously unreported 95-base-pair exon (exon 3b).  In post-
mortem prefrontal cortices of patients with SCZ, mRNA expression of exon 3b was 
significantly reduced, specifically in patients with early-onset SCZ (Uezato et al., 2015).  
How reduced levels of the SAP97 3b transcript may be involved in the susceptibility and 
pathophysiology of early-onset SCZ is unknown.  While our study provides a broad, all-
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around characterization of the effect of Sap97 on brain function, it will be necessary to 
conduct future studies aimed at addressing the individual roles of prominent splice 
variants.   
 
The role of the Serpin family as a molecular module in SCZ  
 The RNAseq study we conducted on the hippocampi of SAP97-cKO animals 
indicated 67 DEGs, which were specifically enriched for SCZ-related risk genes.  The 
specific SCZ-related risk genes we identify in our data are Serping1, Runx3, Clec7A, 
Serpinh1, Cdh1, Ap1S2, Xbp1, Serpind1, and C4b.  These observations lead us to 
hypothesize that Sap97 is a component of a “molecular module” of gene products that 
together subserve aspects of normal behavior.  Further, we hypothesize that 
abnormalities in the operation of this molecular module give rise to select behavioral 
alterations.  Defects in many molecular modules in aggregate manifest as the complex 
psychiatric disorder we recognize as SCZ.  The components of this module may interact 
physically, functionally, developmentally, or in terms of localization.  Future work will be 
required to elucidate: 1) how the components of this hypothesized molecular module 
mechanistically interact, and 2) how this impacts brain function and behavior. 
 Our attention is drawn to three genes that were differentially expressed in the 
hippocampus of SAP97-cKO mice versus controls—serine peptidase inhibitors (serpins), 
as this group of genes has previously been reported in the literature to be associated 
with SCZ (Madani et al., 2003; Hoogendoorn et al., 2004; Saetre et al., 2007; Allswede 
et al., 2017; Chang et al., 2017; Reumann et al., 2017).  SERPING1 was found to be 
upregulated in postmortem brain tissue from SCZ patients (Saetre et al., 2007; Chang et 
al., 2017).  Additionally, a study of adult Swedish twins enriched for SCZ showed an 
association between gene expression level of SERPING1 and thickness across the 
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cortex, a characteristic that is potentially involved in the pathogenesis of SCZ (Allswede 
et al., 2017).   Polymorphisms in the promoter regions of genes on 22q11, a 
chromosomal region that has been associated with various psychiatric illnesses 
including SCZ, resulted in activity differences in the gene SERPIND1 (Hoogendoorn et 
al., 2004).  Another well-studied member of the serpin family previously implicated in 
SCZ, but not directly by our RNAseq data, is neuroserpin (SERPINI1).  SERPINI1 is 
restricted to regions in the brain where synaptic changes are associated with learning 
and memory (cortex, hippocampus, amygdala, and olfactory bulb) (Reumann et al., 
2017).  SERPINI1 has also been implicated in dendrite growth, as overexpression 
studies in primary neurons leads to increased dendritic arborization and altered dendritic 
spine shape (Borges et al., 2010).  Additionally, mice with dysregulated expression of 
Serpini1 show selective reduction of locomotor activity in novel environments, anxiety-
like responses, and neophobic response to novel objects (Madani et al., 2003).  These 
behavioral phenotypes in the Serpini1 deficient mice are reminiscent of the defects we 
see in the SAP97-cKO animals.  Serpini1 is also a known inhibitor of the extracellular 
protease tissue-type plasminogen activator (tPA).  Conditions that affect the activity of 
tPA have consistently been described in drug-naïve cases of SCZ (Halacheva et al., 
2009; Delluc et al., 2013; Song et al., 2014; Gris et al., 2015).  Interestingly, psychotic 
patients on chronic warfarin therapy for deep-vein thrombosis showed remission of 
psychotic symptoms, indicating that defective modulation of the coagulation pathway 
might contribute to the pathogenesis of SCZ (Hoirisch-Clapauch et al., 2015).  C4B, or 
complement component b, is another gene directly listed from our RNAseq study that 
has known roles in the coagulation pathway and is an important cofactor to the serine 
protease family.   The strongest genetic association of SCZ at a population level involves 
variation in the Major Histocompatibility Complex (MHC) locus, where the association of 
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SCZ with the MHC locus arises substantially from many diverse alleles of the C4 genes 
(Rezende, 2003; Schizophrenia Working Group of the Psychiatric Genomics Consortium 
et al., 2016; Allswede et al., 2017). These prior observations along with our findings from 
the SAP97-cKO RNAseq study may highlight the mechanism by which SAP97 
contributes to the etiology of SCZ. 
 
Sex-specific differences in psychiatric disease 
Psychiatric disorders are characterized by substantial sex-differences in their 
prevalence, symptomology, and treatment response (Kokras et al., 2014). Women are 
more likely than men to develop dementia, panic disorder, post-traumatic stress 
disorder, and major depression (Kessler et al., 2008; Wittchen et al., 2011).  Conversely, 
the incidence of neurodevelopmental disorders such as ASD and SCZ is higher in males 
(Fombonne, 2003; Häfner, 2003).  In our study, we conducted RNAseq on male 
hippocampal tissue from SAP97-cKO tissue and found the resulting DEGs to be 
specifically enriched for SCZ risk-related gene sets.  However, our behavioral screen 
was undertaken on both male and female SAP97-cKO animals and identified interesting 
sex-specific differences.  This raises the possibility that the RNAseq profile of female 
SAP97-cKO mice may be at least partially distinct from the male SAP97-cKO dataset.   
One potential limitation of our study of female behavior is the lack of assessment 
of the estrous cycle.  Female mice in distinct stages of the estrous cycle have been 
previously shown to perform differently in behavioral tasks related to anxiety and 
cognition.  Furthermore, it is thought that oestrogens play a protective role against SCZ 
(Kulkarni et al., 2013).  It will be vital to perform behavioral testing at different stages of 
the female estrous cycle, as well as corroborate behavioral findings with RNAseq data in 
order to have a complete understanding of the role of SAP97 in the female brain.  
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Conclusion 
Our study provides the first broad behavioral and transcriptomic characterization 
of Sap97 in the mouse nervous system.  Despite study limitations, we show that loss of 
Sap97 contributes to enrichment of SCZ related genes, as well as behavioral 
abnormalities in both male and female animals.  Our findings are congruous with 
previous literature of monogenic mouse models of psychiatric disorders reporting a 
partial manifestation of the disease phenotype and thus are a first step to understanding 
the molecular mechanism by which SAP97 contributes to neuropsychiatric disorders.     
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FIGURE LEGENDS 
 
Figure 2.1.  SAP97 protein is sufficiently knocked down in SAP97-cKO animals. (A) 
Western blots showing reduced SAP97 band intensity in male SAP97-cKO cerebellum, 
hippocampus, and cortex. (B) Quantification of male western blot analysis. (C) Western blots 
showing reduced SAP97 band intensity in female SAP97-cKO hippocampus and cortex.  (D) 
Quantification of female western blot analysis.  (E) Western blots showing no significant 
changes in SAP97 band intensity between male and female C57Bl/6 animals.  (F) 
Quantification of male versus female C57B/6 western blot analysis.  *P<.05, **P<.01 (two-
tailed Student’s t test).  Data are presented as mean ± SEM. 
 
Figure 2.2 No compensation by Dlg-MAGUK family abundance in SAP97-cKO 
animals.  (A) Western blots and quantification showing no significant change in abundance 
of PSD-95 in cerebellum, hippocampus, and cortex of either male or female SAP97-cKO 
animals. (B) Western blots and quantification showing no significant change in abundance of 
PSD-93 in cerebellum, hippocampus, and cortex of either male or female SAP97-cKO 
animals.  (C) Western blots and quantification showing no significant change in abundance 
of SAP102 in cerebellum, hippocampus, and cortex of either male or female SAP97-cKO 
animals. n.s., no significance (two-tailed Student’s t test).  Data are presented as mean ± 
SEM. 
 
Figure 2.3.  No change in mRNA expression level of AMPAR subunits, selected SAP97 
interactor genes, selected Wnt/β-catenin pathway targets, and selected DISC1 
pathway targets in SAP97-cKO animals.  (A) qPCR results showing no significant change 
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in abundance of Glua1, Glua3, or Glua4 mRNA transcripts in selected brain regions. (B) 
qPCR results showing no significant change in abundance of mRNA levels of selected 
Sap97 interactor genes in selected brain regions.  (C) qPCR results showing no significant 
change in abundance of Wnt/β-catenin pathway targets in selected brain regions.  (D) qPCR 
results showing no significant change in abundance of DISC1 pathway targets in cortex.  
n.s., no significance (two-tailed Student’s t test).  Data are presented as mean ± SEM. 
 
Figure 2.4.  Loss of SAP97 leads to downregulation of DEGs and enrichment of SCZ 
risk-related genes. (A) qPCR verification of top DEG (Sgk1) from RNAseq study.  (B)  Heat 
map representation of downregulation of DEGs in SAP97-cKO hippocampus.  (C) DEGs are 
specifically enriched for SCZ risk-related genes.  *P<.05 (two-tailed Student’s t test), **P<.01 
(hypergeometric probability test). 
 
Figure 2.5. Comparison of open field behavior indicates anxiety-like phenotype in 
both male and female SAP97-cKO animals. (A) No group differences seen in average 
distance traveled in male animals. Female SAP97-cKO animals display significantly less 
distance traveled. (B) No group differences seen in average speed in male animals, while 
female SAP97-cKO show decreased speed. (C) Both male and female SAP97-cKO animals 
show decreased average distance from border of apparatus. n.s., no significance, *P<.05, 
**P<.01 (two-tailed Student’s t test).  Data are presented as mean ± SEM. 
 
Figure 2.6.  Comparison of elevated plus maze behavior between control and SAP97-
cKO animals. (A) No group differences seen in average total time spent in open arms vs 
closed arms of maze. (B) No group differences seen in total open arm entries or closed arm 
entries. (C) No group differences seen in average distance traveled in elevated plus maze 
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apparatus. n.s., no significance (two-tailed Student’s t test).  Data are presented as mean ± 
SEM.   
 
Figure 2.7.  Comparison of cued fear conditioning behavior between control and 
SAP97-cKO animals. (A) Freezing behavior during habituation phase.  Both control and 
SAP97-cKO male and female animals exhibit low levels of freezing with no significant 
differences between groups during habituation. (B) Freezing behavior during testing phase.  
Both male and female SAP97-cKO animals show no differences in freezing behavior 
compared to littermate controls. n.s., no significance (two-tailed Student’s t test).  Data are 
presented as mean ± SEM. 
 
Figure 2.8.  Comparison of novel object recognition behavior indicates male-specific 
cognitive deficit. Control male animals exhibit preference for novel object (Ctrl A-A vs Ctrl 
A-B), while SAP97-cKO male animals do not show preference.   Both control and SAP97-
cKO female animals show trend for preference of novel object, but did not reach 
significance.   n.s., no significance, **P<.01 (ordinary one-way ANOVA with Tukey’s test for 
multiple comparisons).  Data are presented as mean ± SEM. 
 
Figure 2.9.  Comparison of rotarod behavior indicates female-specific motor learning 
deficit.  (A) Both control and SAP97-cKO male animals show learning over the 4-day 
course of rotarod paradigm.  Control female animals show increased motor learning over 
course of 4 days, while female SAP97-cKO show no significant increase in motor learning.  
(B) Plots showing comparison of Day 1 versus Day 4 rotarod data for control and SAP97-
cKO animals indicates female-specific motor learning deficit. (C) Aged SAP97-cKO males 
show learning impairment over the 4-day course of rotarod.  Both aged control and SAP97-
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cKO female animals show no significant increase in motor learning, however, aged female 
SAP97-cKO animals have significantly worse performance on the task as compared to aged 
littermate controls.  (D) Plots showing comparison of Day 1 versus Day 4 rotarod data for 
aged control and SAP97-cKO animals.  n.s., no significance, **P<.01, ***P<.001 (repeated-
measures two-way ANOVA with Tukey’s test for multiple comparisons).  Data are presented 
as mean ± SEM. 
 
Figure 2.10.  Comparison of social choice behavior between control and SAP97-cKO 
animals.  (A) No significant differences observed between control and SAP97-cKO male or 
female animals in preference for social target. (B) No significant differences observed 
between control and SAP97-cKO male animals in preference for sniffing/investigating social 
target.   **P<.01, ***P<.001, ****P<.0001 (ordinary one-way ANOVA with Tukey’s test for 
multiple comparisons).  Data are presented as mean ± SEM.  
 
57 
 
Table 2.1. List of genes with significant expression differences between control 
and SAP97-cKO mice. 
Ensemble Genome ID Gene Symbol Log Fold Change 
ENSMUSG00000019970 Sgk1 -0.604982801 
ENSMUSG00000022770 Dlg1 -0.920172279 
ENSMUSG00000023224 Serping1 -1.092300119 
ENSMUSG00000029304 Spp1 -2.086028102 
ENSMUSG00000031431 Tsc22d3 -0.662945543 
ENSMUSG00000021390 Ogn -1.36634343 
ENSMUSG00000026728 Vim -0.73795218 
ENSMUSG00000022769 Sdf2l1 -0.813450163 
ENSMUSG00000020467 Efemp1 -0.785266079 
ENSMUSG00000033227 Wnt6 -1.860240362 
ENSMUSG00000055128 Cgrrf1 -0.544558433 
ENSMUSG00000037254 Itih2 -1.44816667 
ENSMUSG00000070691 Runx3 -2.433336132 
ENSMUSG00000032575 Manf -0.581728345 
ENSMUSG00000031289 Il13ra2 -1.998579379 
ENSMUSG00000029661 Col1a2 -1.062558267 
ENSMUSG00000067038 Rps12-ps3 2.467941625 
ENSMUSG00000054619 Mettl7a1 -0.39870621 
ENSMUSG00000024650 Slc22a6 -1.704915114 
ENSMUSG00000015090 Ptgds -1.253057418 
ENSMUSG00000026043 Col3a1 -1.300397001 
ENSMUSG00000030357 Fkbp4 -0.343944084 
ENSMUSG00000071005 Ccl19 -2.363646432 
ENSMUSG00000105843 Gm42644 -1.52239332 
ENSMUSG00000030711 Sult1a1 -0.875568486 
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ENSMUSG00000079293 Clec7a -2.007730582 
ENSMUSG00000070436 Serpinh1 -0.658564574 
ENSMUSG00000030154 Klrb1f -2.174662835 
ENSMUSG00000004951 Hspb1 -1.133328217 
ENSMUSG00000036777 Anln -0.750523147 
ENSMUSG00000027248 Pdia3 -0.350126593 
ENSMUSG00000030218 Mgp -1.053034845 
ENSMUSG00000030108 Slc6a13 -1.258734628 
ENSMUSG00000057836 Xlr3a -2.154616401 
ENSMUSG00000000303 Cdh1 -1.987938463 
ENSMUSG00000024087 Cyp1b1 -0.95956574 
ENSMUSG00000032231 Anxa2 -0.831693618 
ENSMUSG00000060591 Ifitm2 -0.82147731 
ENSMUSG00000049241 Hcar1 -1.730353275 
ENSMUSG00000032060 Cryab -0.561687665 
ENSMUSG00000026638 Irf6 -1.238846117 
ENSMUSG00000022548 Apod -0.868596841 
ENSMUSG00000013584 Aldh1a2 -1.291353747 
ENSMUSG00000019539 Rcn3 -0.615255839 
ENSMUSG00000040055 Gjb6 -0.57564983 
ENSMUSG00000040310 Alx4 -1.225356858 
ENSMUSG00000031367 Ap1s2 -0.377838987 
ENSMUSG00000023272 Creld2 -0.51269519 
ENSMUSG00000038155 Gstp2 -1.96171475 
ENSMUSG00000107215 Gm43197 -2.106413397 
ENSMUSG00000074896 Ifit3 -0.830338737 
ENSMUSG00000020484 Xbp1 -0.420933711 
ENSMUSG00000034435 Tmem30b -2.348757156 
ENSMUSG00000022766 Serpind1 -1.521272379 
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ENSMUSG00000005125 Ndrg1 -0.558146377 
ENSMUSG00000038393 Txnip -0.584362558 
ENSMUSG00000041548 Hspb8 -0.559621993 
ENSMUSG00000034165 Ccnd3 -0.399017781 
ENSMUSG00000027048 Abcb11 -2.19248413 
ENSMUSG00000073418 C4b -0.516645555 
ENSMUSG00000025823 Pdia4 -0.55418986 
ENSMUSG00000031070 Mrgprf -1.766073987 
ENSMUSG00000032179 Bmp5 -1.738362368 
ENSMUSG00000043795 Prr33 -2.024615333 
ENSMUSG00000048368 Omd -2.520720092 
ENSMUSG00000066861 Oas1g -2.341011247 
ENSMUSG00000024371 C2 -1.517189655 
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Table 2.2A. List of top diseases identified through IPA that were affected in 
hippocampus of SAP97-cKO animals. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Name p-value Genes Affected 
Organismal Injury and 
Abnormalities 
2.58E-02 - 1.30E-05 
 
37 
 
Respiratory Disease 
2.52E-02 - 1.30E-05 
 
10 
 
Endocrine System Disorders 
2.52E-02 - 1.42E-05 
 
16 
 
Gastrointestinal Disease 
2.21E-02 - 1.42E-05 
 
21 
 
Immunological Disease 
2.52E-02 - 1.42E-05 
 
14 
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Table 2.2B.  List of top molecular and cellular functions identified through IPA that 
were affected in hippocampus of SAP97-cKO animals.   
 
 
 
Name p-value Genes Affected 
Cell Death and Survival 
2.83E-02 - 5.79E-05 
 
21 
 
Cellular Movement 
2.52E-02 - 6.58E-05 
 
18 
 
Cell Morphology 
2.52E-02 - 2.70E-04 19 
 
Cellular Development 
2.52E-02 - 2.70E-04 25 
 
Cell-To-Cell Signaling and 
Interaction 
2.47E-02 - 3.32E-04 
 
17 
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Table 2.2C.  List of top networks identified through IPA that were affected in 
hippocampus of SAP97-cKO animals 
 
 
ID Associated Network Functions Score 
Organismal Injury and Abnormalities, Respiratory 
Disease, Cellular Movement 
35 
Cellular Development, Cellular Growth and 
Proliferation, Hematological System Development 
and Function 
22 
Ophthalmic Disease, Organismal Injury and 
Abnormalities, Hereditary Disorder 
22 
Cell Cycle, Gene Expression, Skeletal and 
Muscular System Development and Function 
5 
Developmental Disorder, Embryonic Development, 
Organ Development 
2 
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CHAPTER 3: GENERAL CONCLUSIONS AND FUTURE DIRECTIONS 
 
 In this thesis work, I have attempted to further understand the direct role of 
SAP97 in psychiatric disorders, such as ASD and SCZ.  In Chapter 2, I characterize 
mice conditionally lacking Sap97 in the nervous system at the behavioral and 
transcriptomic level.  I find that while SAP97-cKO mice have relatively subtle behavioral 
deficits, loss of Sap97 results in an enrichment of SCZ risk-related DEGs.  Below, I will 
describe the implications for this work and discuss remaining questions for future work.   
 
THE MOLECULAR MODULE HYPOTHESIS 
 Investigations of ASD, SCZ, and other related psychiatric disorders indicate a 
highly polygenic architecture with small effect sizes of each implicated risk variant.  
Mouse modeling of these disorders by targeting one such risk variant typically 
demonstrates a moderate, or incomplete manifestation of the human disorder, as 
discussed in the Introduction of this thesis.  Results from this thesis work coincide with 
previous results indicating psychiatric disorders to be polygenic in nature.  While SAP97-
cKO mice did not show robust changes across the behavioral domains related to ASD 
and/or SCZ, we observed subtle, sex-specific abnormalities.  Likewise, loss of Sap97 
resulted in mild changes at the transcriptomic level as well, with 67 DEGs.  However, 
this DEG set was enriched for SCZ risk-related genes, where 4 of 9 of these SCZ risk 
genes play a role in common pathways.  These genes are Serping1, Serpinh1, 
Serpind1, and C4b.   
This first three of these genes (Serping1, Serpinh1, Serpind1) are known as 
serine protease inhibitors, or serpins.  Protease inhibition by serpins controls an array of 
biological processes, including coagulation and inflammation, and this family of genes 
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has previously been reported in the literature to be associated with SCZ (Madani et al., 
2003; Saetre et al., 2007; Borges et al., 2010; Chang et al., 2017; Reumann et al., 2017; 
Weickert et al., 2018).  C4B, or complement component b, has known roles in the 
coagulation pathway and is an important cofactor to the serine protease family.  The 
strongest genetic association of SCZ at a population level involves variation in the Major 
Histocompatibility Complex (MHC) locus, where the association of SCZ with the MHC 
locus arises substantially from many diverse alleles of the C4 genes (Rezende, 2003; 
Hoirisch-Clapauch et al., 2015; Schizophrenia Working Group of the Psychiatric 
Genomics Consortium et al., 2016).   
 These findings suggest that Sap97 is a member of a tight cluster of genes, or 
“molecular module” that interacts and subserves aspects of normal behavior.  Defects in 
many molecular modules in aggregate may result in the complete manifestation of the 
disorder.  The components of this module may interact physically, functionally, 
developmentally, or in terms of localization.  In order to elucidate how the components of 
this hypothesized molecular module interact, and how this impacts organismal behavior, 
a number of experiments can be done.  Below, I outline a few potential future 
experiments to address these questions. 
 
Interaction within the SAP97 molecular module 
 One question to be addressed is whether Sap97, Serping1, Serpinh1, Serpind1, 
and C4b physically interact.  One method to address this question would be by 
coimmunoprecipitation (CoIP) experiments.  We can begin by overexpressing Sap97 
and one or a combination of SCZ risk genes in HEK cells, and subsequently perform 
CoIP.  We may additionally examine whether this molecular module interacts 
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endogenously by performing CoIP experiments on brain tissue lysate generated from 
control and SAP97-cKO animals.   
 It is also plausible that the SAP97 molecular module interacts in the region-
specific manner.  For example, members of the serpin family, such as SERPINI1, are 
restricted to regions in the brain where synaptic changes are associated with learning 
and memory (i.e. cortex, hippocampus, amygdala).  One could argue that as a 
scaffolding protein with multiple protein-protein binding domains, SAP97 may aid in 
tethering members of the molecular module to synaptic regions, where they act together 
to ensure proper synapse formation, function, and behavioral output.  To address this 
question, we can prepare synaptosomes from control and SAP97-cKO animals and 
examine physical interaction within this proposed molecular module.  
 Previous evidence from the literature also suggests that members of the SAP97 
molecular module may interact functionally as well.  For example, the serpin family of 
genes, namely Serpini1, has also been implicated in dendrite growth (Borges et al., 
2010; Reumann et al., 2017).  And similar to SAP97, overexpression studies in primary 
neurons leads to increased dendritic arborization (Borges et al., 2010).  Additionally, 
characterization of mice lacking Schnurri-2, or MHC-binding protein 2, show immature 
dendritic spine morphology characterized by increases in spine length and decreases in 
spine diameter (Nakao et al., 2017).  Schnurri-2 knockout mice also exhibited increases 
in C4b gene, which is thought to mediate synapse elimination during postnatal 
development, and show SCZ-like behaviors (Takao et al., 2013).  Other observed 
changes in these mice included a significant reduction in GLUA1 and a trend for 
decreased expression of PSD-95, both of which have strong association with SAP97 
(Nakao et al., 2017).  Overall, these results suggest that the SAP97 molecular module 
we have identified may possibly function at the synapse and play a role in dendrite and 
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spine morphology, and ultimately, proper behavioral output.  We can attempt to address 
this question in the future by conducting co-knockdown experiments (i.e. knockdown of 
serpin family/C4B in addition to SAP97) and using dendritic growth as a readout.  We 
can also employ the use of targeted viral vectors to further the knockdown level of other 
module members within the SAP97-cKO mice.  It is plausible that a more severe 
knockdown effect of this module will result in a larger behavioral defect compared to 
what we observed in our studies.   
 
Neuroinflammation and psychiatric disorders     
 Results from previous studies also indicate that our identified SAP97 molecular 
module may also serve as a potential interface between inflammation and synaptic 
dysfunctions.  Inflammation has been posited as a potential mechanism underlying the 
development and progression of SCZ and other related neuropsychiatric disorders, and 
meta-analyses have demonstrated that patients with SCZ reliably exhibit increased 
markers of inflammation (Potvin et al., 2008; Miller et al., 2011; Goldsmith et al., 2016; 
Miller and Goldsmith, 2016; Schizophrenia Working Group of the Psychiatric Genomics 
Consortium et al., 2016).  Furthermore, there is growing literature showing that 
increased inflammatory cytokines may be linked to negative symptoms in patients with 
SCZ (Garcia-Rizo et al., 2012; Liu et al., 2012; Asevedo et al., 2014; Kissi et al., 2018).  
In particular, TNFα and interleukin-6 were found to be associated with deficit syndrome, 
a distinct subtype of SCZ characterized by primary and enduring negative symptoms 
(Goldsmith et al., 2018).  A previous study identified TNFα as a critical molecule involved 
in the synaptic alterations seen in mice with experimental autoimmune encephalomyelitis 
(EAE), an animal model of brain inflammation (Centonze et al., 2009).  TNFα has the 
potential to promote dendritic spine loss in EAE brains through an excitotoxic 
77 
 
mechanism (Centonze et al., 2009). SAP97 also binds to TNFα converting enzyme 
(TACE) via the SAP97 PDZ3 domain (Peiretti, 2003).  Interestingly, overexpression of 
SAP97 reduced the release of three different TACE-processed substrates, including 
TNFα (Peiretti, 2003).  This suggests that SAP97 participates in regulating the 
inflammatory response.   Given that the serpin family of genes and C4B are also known 
to play important roles in the inhibition of the inflammatory response, an interesting 
potential future experiment would be to examine inflammation in the SAP97-cKO 
animals by measuring levels of cytokines such as TNFα and interleukin-6 in plasma 
collected from control and SAP97-cKO animals.  As the SAP97 molecular module is 
downregulated in the SAP97-cKO animals, we would expect these animals to have a 
heightened immune response.  This increased immune response could be a potential 
mechanism underlying the specific behavioral deficits observed in the SAP97-cKO mice, 
and may serve as a target for therapeutic intervention. 
 
ENVIRONMENTAL MODELS OF PSYCHIATRIC DISORDERS IMPLICATE IMMUNE 
RESPONSE 
 In this thesis work, we have chosen to focus predominately on examining and 
modeling the genetic etiology of psychiatric disorders.  However, genetics do not 
account for all patient cases, and environmental factors are thought to contribute 
significantly to disease risk.  Multiple environmental rodent models of psychiatric 
disorders implicate a heightened immune response.    
 A commonly-used environmentally induced model of ASD is the propionic acid 
(PPA) model.  PPA is a short chain fatty acid, a metabolic end-product of enteric 
bacteria in the gut, and a common food preservative.  Various studies have indicated 
that PPA causes ASD-like behaviors and neuroinflammatory response in rats (MacFabe 
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et al., 2007; Shultz et al., 2008; MacFabe et al., 2011).  For example, Shultz et al. 
reported that exposure to PPA resulted in impaired social behavior measured as 
distance apart, proximity, and play behavior in rats (Shultz et al., 2008).  MacFabe et al. 
demonstrated that rats treated with PPA showed restricted behavioral interest to a 
specific object among a group of objects, impaired social behavior, and impaired 
reversal in a T-maze task compared to controls, in addition to reactive astrogliosis and 
activated microglia in the brain (MacFabe et al., 2011).   
As SCZ is considered a neurodevelopmental disorder, early environmental 
factors potentially play a role in the etiology of the disease.  One early life factor 
associated with SCZ is maternal infection during pregnancy (Brown and Derkits, 2010).  
Early epidemiological studies found an increased rate of SCZ among offspring who were 
in utero during major influenza epidemics as compared to non-epidemic periods (Brown 
and Derkits, 2010).  This association was replicated in several geographic populations 
(Brown and Derkits, 2010).  Additional studies found an increased risk of SCZ among 
offspring of mothers who received diagnosis of influenza, toxoplasmosis, rubella, or 
bacterial infection during pregnancy (Brown et al., 2000; Brown et al., 2004; Brown et al., 
2005; Sorensen et al., 2009).  High levels of pro-inflammatory cytokines in the maternal 
serum during pregnancy were also found to increase risk of SCZ in in utero offspring 
(Canetta et al., 2014).  Maternal immune activation (MIA), is not specific to 
schizophrenia, but may also increase the risk for ASD, bipolar disorder, and depression 
(Canetta et al., 2014).   
Several groups have studied prenatal infection in rodent models.  Both direct viral 
infection of the fetus, as well as abnormal activation of the maternal immune system, 
resulted in behavioral impairments relevant to SCZ (Shi et al., 2002; Shi et al., 2005; 
Meyer and Feldon, 2012).  The maternal immune system can be activated with a 
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synthetic double-stranded RNA, polyinosinic-polycytidylic acid (PolyIC).  The PolyIC 
model of SCZ has gained wide recognition in the scientific community as it successfully 
accounts for several aspects of SCZ: epidemiology, pathophysiology, symptomology, 
and treatment (Meyer and Feldon, 2012).   
 PolyIC is a commercially available synthetic analog of double-stranded RNA.  
Double-stranded RNA is generated during viral infection as a replication intermediate for 
single-stranded RNA or as a byproduct of symmetrical transcription in DNA viruses 
(Takeuchi and Akira, 2007).  It is recognized as a foreign by the mammalian immune 
system through the transmembrane protein toll-like receptor 3 (TLR3) (Alexopoulou et 
al., 2001).  Upon binding to TLRs, double stranded RNA, or the synthetic analog PolyIC, 
stimulates production and release of many pro-inflammatory cytokines, including 
interleukin-1B, interleukin-6, and TNFα (Fortier et al., 2004; Cunningham et al., 2007).  
PolyIC is also a potent inducer of the type 1 interferons INF-a and INF-b (Kimura et al., 
1994; Traynor et al., 2004).  Administering PolyIC can therefore mimic the acute phase 
response to viral infection.  Maternal exposure to PolyIC is capable of altering pro- and 
anti-inflammatory cytokine levels in the three relevant compartments of the maternal-
fetal interface of rodents, namely the placenta, amniotic fluid, and the fetus (Meyer et al., 
2006).  This allows the model to include aspects of maternal/fetal inflammation, taking 
into account one of the most relevant immunological mechanisms suggested to be 
crucial for mediating the long-term effects of prenatal infection on brain and behavioral 
development (Patterson, 2009; Meyer et al., 2016).  The PolyIC mouse model of SCZ 
recapitulates behavioral phenotypes such as sensorimotor gating deficits, impaired 
working memory, and reduced social behavior (Ibi et al., 2009).   
 Increased susceptibility to environmental stress remains an open question in the 
SAP97-cKO animals.  As discussed earlier, the literature supports the idea that inhibition 
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of the SAP97 molecular module may induce a heightened immune response in the 
SAP97-cKO animals.  However, as the behavioral deficits observed were moderate, it is 
plausible to assume that the potential immune response in these animals was not 
sufficient to induce a large-scale behavioral effect.  A complementary experiment to 
using targeted viral vectors to further the knockdown level of other SAP97 molecular 
module members would be to expose SAP97-cKO animals to environmental stress (i.e. 
maternal immune activation), and measure whether we obtain a more complete 
manifestation of SCZ as compared to the environmental stress or SAP97-cKO model 
alone.  Results from these proposed experiments would elucidate the mechanism by 
which loss of SAP97 contributes to the etiology of SCZ.   
 
LIMITATIONS OF RODENT MODELS 
 How useful are rodent models, in general, for understanding human psychiatric 
disorders?  Animal models aim to recapitulate behavioral symptoms, but this approach 
has limitations as some of the behavioral symptoms are distinctive for humans and are 
not measurable in animals (i.e. delusions or hallucinations) (Canetta and Kellendonk, 
2018).  Additionally, compensatory mechanisms present in mice may not have the same 
effects in humans (Deconinck et al., 1997). 
 One classical example is the mdx mouse model for Duchenne muscular 
dystrophy (DMD).  DMD in humans is caused by lack of dystrophin, a large membrane-
associated protein expressed in muscle and the brain (Tinsley et al., 1994).  The mdx 
mouse model lacks dystrophin due to a mutation that results in a premature stop codon, 
but presents with a much milder form of the disease than in humans (Bulfield et al., 
1984).  Compensation for lack of dystrophin by structurally related proteins such as 
utrophin may also be more successful in the mouse, leading to a milder phenotype than 
81 
 
in humans (Deconinck et al., 1997).  Dystrophin/utrophin double knockout mice have 
been generated and present with many more clinical signs of DMD than mdx mice 
(Deconinck et al., 1997).  Nevertheless, the mdx mouse model is a popular model for 
studying DMD and has proven useful for examining potential therapeutics and molecular 
mechanisms underlying the disorder. 
 The story of the mdx mouse model may also be true for the SAP97-cKO model.  
SAP97 has wide molecular diversity, which is created by extensive alternative splicing.  
Uezato and colleagues identified a new SAP97 splicing variant that is transcribed from a 
previously unreported 95-base-pair exon (exon 3b) (Uezato et al., 2015).  In post-
mortem prefrontal cortices of patients with SCZ, mRNA expression of exon 3b was 
significantly reduced, specifically in patients with early-onset SCZ (Uezato et al., 2015).  
However, this exon is primate-specific (Uezato et al., 2017).  It is plausible that this 
primate-specific exon of SAP97 is responsible for contributing to a more severe 
manifestation of SCZ in humans, while loss of mouse SAP97 is more easily 
compensated for by other genes.  In this thesis work, we have shown that loss of SAP97 
is not compensated for by change in overall abundance of the other Dlg-MAGUK family 
members.  This does not rule out compensation in terms of localization (i.e. at the 
synapse versus whole tissue) or by activity.  These open questions should be addressed 
in the future to further understand SAP97’s role in disease in humans versus the mouse.  
 
 Difficulty in using DSM criteria for rodent models of psychiatric disorders 
 An additional complication with using rodents to model psychiatric disorders is 
determining how symptoms in an animal model add up to a recognized human disorder.  
The Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IVTR) 
contains scant knowledge of the pathophysiology underlying these disorders (Nestler 
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and Hyman, 2010).  Diagnoses are based solely on phenomenology, such as symptoms, 
signs, and course of illness.  As a result, the boundaries between DSM-IVTR disorders, 
and the boundaries between disorder and normal variation, are unclear (Hyman, 2010).  
For example, two patients with major depression may exhibit no overlap of the 9 
symptoms listed in the DSM criteria for Major Depressive Episode.  The multiple 
symptom combination, in addition to the inability to assess certain symptoms in mice, 
means that different mouse models of depression would have little in common (Nestler 
and Hyman, 2010).  This issue is extended to a variety of psychiatric disorders, including 
ASD and SCZ.   
 Additionally, DSM-IVTR diagnoses do not currently map onto abnormalities of 
molecules, synapses, cells, or neural circuits for psychiatric disorders.  There are no 
molecular or cellular abnormalities in the human disease which could validate potential 
phenomenology in an animal (Nestler and Hyman, 2010).  Individual symptoms 
observed in animal models may not have a simple, straightforward correspondence to 
human symptoms.  As a result, animal models are unlikely to mirror the full extent of a 
given psychiatric disorder.  While animal models of disease are useful, it is necessary to 
keep in mind the imperfections of rodent models when interpreting results. 
  
CONCLUSIONS 
 This thesis work provides the first broad behavioral and transcriptomic 
characterization of SAP97 in the mouse nervous system.  Despite study limitations, we 
show that loss of SAP97 contributes to enrichment of SCZ related genes, as well as 
moderate sex-specific behavioral abnormalities.  We have potentially identified a module 
of genes where SAP97 and the serpin/C4B family are participants, whose role is to 
regulate inflammatory response in the nervous system.  While we have taken the first 
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steps to elucidate the contribution of SAP97 to psychiatric disorders, further investigation 
is needed to validate the “molecular module” hypothesis and fully understand the 
downstream pathways and behaviors affected by this module.  Further understanding of 
the role of SAP97 in regulating inflammatory response and behavior may identify new 
targets for therapeutic intervention.   
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